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Neural interface technologies with implantable microelectrode arrays hold great promise 
for treating neural injuries or disorders. On neural electrode surfaces, conducting polymers can 
be electropolymerization with negatively charged molecules incorporated. When the polymer is 
reduced with negative current, dopant molecules are released from the polymer. This feature can 
be utilized to deliver neural transmitters and modulators from the electrodes to alter neural 
network activity. Previously, release of CNQX (6-cyano-7-nitroquinoxaline-2,3-dione), an 
AMPA (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) receptor antagonist in 
hippocampal neuron culture effectively suppressed local neural activity in a transient manner. In 
this study, we further advance this technology by characterizing the drug loading and release 
capacity from microelectrodes, expanding the range of candidate dopants, and demonstrating in 
vivo effectiveness in rat somatosensory (S1) barrel cortex. 
Firstly, to quantify the concentration of released drug, fluorescent model molecule was 
used and quantitatively assessed in a real time imaging system. Stimulation amplitude was varied 
to determine the amount of released drug from microelectrodes. Secondly, only negatively 
charged drugs have been effectively released in the past. In this study, zwitterionic transmitter γ-
Aminobutyric acid (GABA) was successfully delivered with the technique, greatly expanding the 
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applicable range for the technique. Finally, we used evoked response from barrel cortex to 
evaluate the release of DNQX (6,7-dinitroquinoxaline-2,3-dione), an analog of CNQX.  The 
neural activity of barrel cortex reliably represents sensory stimuli from whiskers, hence provides 
an excellent in vivo network model for evaluating our neurochemical release system. Neural 
activity from multi-whisker stimulation was immediately and locally suppressed by released 
DNQX for one to six seconds, demonstrating the high spatial-temporal resolution of the 
technique. Furthermore, weaker activities were nearly abolished by released DNQX whilst 
stronger activities were less influenced, because the strong over-saturated neural input can only 
be partially antagonized. The system demonstrates successful modulation of neural network 
activity in a highly controllable manner. With the ease of being incorporated in existing neural 
implants without increasing the volume or complexity, this technology may find use in a wide 
range of neuroscience studies and potentially therapeutic devices. 
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1.0  INTRODUCTION 
The application of implantable microelectrode arrays to directly interface the neural 
tissue and restore lost functions or treat neural disorders have demonstrated great promises in 
recent years. Brain computer interface technology to enable the movement computer controlled 
devices with the intention of decoded neural signal is a broadly known successful application of 
the in vivo MEA implantations. Another important application of MEAs are the simultaneous 
recording and stimulation of functional neural networks to understand the spatial temporal 
pattern of a large population of neurons. Both the neuroscience research and clinical application 
of MEA benefit from the capability to modulate the neural activity of the recorded neural 
network to dissect the functions of various network components in a complex behavior. 
However, the manufacture of MEAs requires highly delicate and complex micro fabrication 
techniques and the addition of fluidic channels or fiber optics for the neural modulation often 
tremendously increase the fabrication difficulty and the failure rate during the process. The 
utilization of electrochemically synthesized conducting polymers can bypass these difficulties by 
directly modify the recording or stimulation electrode and delivery neuroactive molecules to the 
local neural network without impeding the extracellular recording of MEAs. 
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1.1 NEURAL RECORDING AND STIMULATION ON MICROELECTRODE 
ARRAY 
Multi-electrode array (MEA) provide the unique benefit of simultaneous recording and 
stimulation from a large number of neurons. MEAs for both in vitro and in vivo applications 
have been developed for interfacing with neural networks. The in vitro MEAs are developed for 
the purpose of high throughput test bed for drug selection[1] or the understanding of theories 
about spatial temporal firing patterns[2] of neural networks, due to the relative low cost and high 
channel count to utilize this technology. In comparison, in vivo MEAs are often used for 
decoding intention of neural network activity[3] or modulate disease affected abnormal neural 
firing patterns[4] because in vivo MEAs can directly interface with neural networks underlying 
various cognitive process.  
1.1.1 In vitro MEA 
The advantage of in vivo MEA implantation lies in the direct investigation of neural 
network in an intact animal with the context of neural functionality. But the technique is 
restricted to relatively small number of trials due to multiple reasons, including the difficulty in 
surgically implanting the MEA[5, 6], the chronic failure of the device[7, 8], the highly complex 
process to manufacture in vivo MEA in large quantities[9-11] lead to high cost of the device with 
limited channel numbers. The in vitro preparation serves as a simplified alternative to study the 
property of neurons and isolated neural networks by electrophysiology techniques. The earliest 
work on isolated Loligo giant axons [12-16] lay the foundation of our understanding towards the 
membrane dynamics mechanism of action potentials as well as the active channel conductance 
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change during neural signaling process. The study of isolated neurons are ideal for basic neural 
electrophysiology research because the simplified system is essentially free from random 
variabilities from unknown source during complex in vivo neural processes. Additionally, the 
traditional single cell recording technologies such as patch clamp are limited to a very small 
number of neurons to be investigated simultaneously, but the in vitro MEA allow high 
throughput recording of neurons thus benefit drug selection and toxicity study as well as possible 
big data analysis of neural properties and classifications. First in vitro MEA application 
[17]instantly increased the number of simultaneously recordable neurons and allow the study of 
spatial temporal neural dynamics generated by a simplified neural network. The use of MEAs 
have also expanded to the understanding of generation mechanisms underlying spontaneous 
neural network firing patterns[2] as well as electrical stimulation parameter optimization for 
direct and highly efficient modulation of neural activities [18]. Another intriguing application of 
in vitro MEAs is the generation of a simplified brain mimicking neural network culture for 
controlling external device based on specific input information transduced by electrically 
stimulate the neural networks in spatial temporal patterns [19-21]. These works are still 
preliminary but create an exciting outlook for the future use of neural technologies. 
1.1.2 In vivo MEA 
One of the most promising use of in vivo MEA for brain computer interface technology is 
the control of external devices with intentions decoded from motor cortex recordings [22-24]. 
The neural signal extracted from motor cortex allows the direct control of robotic arms[25-27] or 
virtual cursor[28, 29]. The application of this technology will not only benefit our understanding 
in motor planning process, but also restore the lost motor function of patients with full or partial 
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paralysis [30-32]. The device to interface with neural tissue directly and obtain useful neural 
signal for decoding brain intention is the implantable multi-electrode array [22, 31, 33]. Efforts 
have also been made to create less invasive recording techniques with electroencephalogram 
(EEG) [29]or electrocorticography (ECoG)[34] recording capabilities. To decode precise 
information for better controllability over the device, high density and high channel count MEAs 
are usually preferred.  
Many types of micro wire arrays and silicon based micro fabricated arrays have been 
developed as in vivo MEAs. Micro fabrication technology can produce MEAs with very high 
reproducibility and precisely controlled electrode distributions, while the traditional micro wire 
arrays require less complicated device and procedures during the manufacture yet capable of 
providing good signals [8, 35]. Among silicon based microelectrode arrays, Both the tip 
recording Utah arrays[36] and the shank recording Michigan probes[37, 38] have demonstrated 
high quality single unit recording capabilities. 
 A major hindrance to the application of BCI device for treatment of any paralysis patient 
is the chronic degradation of unit recording performance [8, 22, 36, 39, 40]. Various mechanisms 
have been linked to the device failure including both biological[41, 42] and abiological source 
such as mechanical[43] or material[39].  
With the complex fabrication process and difficulties in recording meaningful neural 
signals of implantable MEAs, it is critical to develop neural modulation techniques with 
simplicity to adapt without interfering with neural recording function kept in mind. Because real 
time modulation of recorded neurons one of the most important techniques to successfully study 
of neural network functions underlying various neural network firing mechanisms[44-47]. 
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1.2 LOCAL PHARMACOLOGICAL INTERVENTIONS FOR NEUROSCIENCE 
RESAERCHER 
1.2.1 Benefit of local neural network modulation 
Bi-direction BCI with capability to adjust motor control by sensory feedback input[48] or 
the close-loop neural stimulation devices[49, 50] for precise treatment of epilepsy have been of 
interest due to the capability to optimize device output based on the real time information from 
the modulation target. Besides the translational studies for restoration of lost neural function or 
treatment of neural disorders, simultaneous modulation of recorded neural networks also benefit 
the understanding of various receptors and subpopulation of neurons underlying particular neural 
activities[51-53]. The introduction of dopamine, 5-HT and GABA receptor modulation by 
iontophoresis[45, 54-56] and microinjection[57] helped elucidate the involvement of these 
receptors in the working memory process. Antagonizing different glutamate receptor species 
during the rat somatosensory processing with iontophoresis also helped understanding the 
contribution of various glutamate receptors during a whisker sensation event [47]. 
1.2.2 Local neural modulation techniques and limitations 
Conventional neural modulation techniques include systemic perfusion [58] or localized cannula 
injection in a local area [57, 59]. However many study requires the use of pharmacological 
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perturbation to neural networks with high spatial and temporal resolutions beyond the limitation 
of these methods [53, 60-63]. Techniques such as pressurized injection [64-66], micro 
iontophoresis [47, 54, 55, 67], and microfluidics devices [68, 69]have been developed for more 
precisely controllable delivery of chemicals to local neural networks. The previous two 
techniques require additional positioning of fluidic channels without interfering with the fragile 
implantable MEA, and the microfluidics device remarkably increase the difficulty of device 
fabrication due to additional microfabrication steps. Furthermore all these local neural 
modulation techniques requires additional pump, valve, fluidic channels, and they often suffer 
from drug leakage or tip clogging due to the formation of glial scar around the foreign device. 
The development of optogenetics provide the capability of modulating a subpopulation of 
genetically modified neurons with high temporal resolution[70-74], and the devices implemented 
with optogenetics technology have demonstrated the capability to simultaneously record neural 
activity and optically control the firing of neural networks[75, 76]. However the device also yield 
a bulky size and require complex fabrication process due to the incorporation of fiber optics next 
to the recording microelectrode array. Additionally, the genetic modification of neurons for 
clinical applications require very cautious considerations thus add further steps before the 
product can be utilized, and the use of optical manipulation requires additional light generating 
device as well as fiber optics. 
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1.3 CONDUCTIONG POLYMRES 
1.3.1 Synthesis and properties of conducting polymers  
The first development of conducting polymer occurred in mid-19th century when Henry 
Letheby first polymerized polyaniline and conducted research on the unique properties[77]. 
Conducting polymer had since found use in many fields including electronics[78], energy 
storage[79], sensors [80-82], biointerfacing [83] and tissue engineering [84]. Because conducting 
polymers are intrinsically conductive for both electrons and chemicals, they resembles the 
properties of neural tissue to a certain extent, because neural signaling involves the process of 
conversion between electrical and chemical signals [85-87]. The conducting polymers 
Polypyrrole (PPy) and poly(3,4-ethylenedioxythiophene) (PEDOT) are among the most commonly 
utilized conducting polymers for neural interface[88-93]. PPy and PEDOT are the main material for 
this thesis due to their unique beneficial properties for improving neural interface and delivery 
neurochemicals [93-96]. The polymerization process of PPy with incorporated dopant molecule A is 
illustrated in Fig 1, in which the polymer is deposited onto electrode surface with 0.8 V oxidation 
potential. 
The synthesis of conducting polymer can be realized by electrochemical deposition[92] 
as illustrated in Fig. 1-1, or can be achieved via chemical reactions such as free radical 
polymerization[97]. The polymer generated by potentiostat or galvanostat electrochemical 
deposition can only form on conductive surface while chemical synthesis can generate 
conducting polymer on any surface[98]. The chemically synthesized conducting polymer is best 
suitable for scaling up product in large quantities, but the homogeneity of the internal structure is 
usually hard to control and requires careful optimization[99]. In contrast the electrochemically 
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synthesized conducting polymer usually form a thin layer of film and modulate the surface 
property of the electrodes[89]. The electrochemically synthesized conducting polymer film [96, 
100] lays out the foundation of the drug delivery study in this thesis.  
 
.  
Figure 1-1 Electrochemical synthesis of PPy with Chronoamperometry technique. The solution of Py 
monomer can form conducting polymer on working electrode of electrochemical cell with oxidation potential 
around 0.8 V. The conjugated polymer chain maintain positive charged and the negatively charged ions A in the 
solution was electrostatically incorporated into the polymer. The synthesis of PPy result in pH change due to the 
formation of protons.  
 
1.3.2 Redox property of conducting polymers 
One unique property of the conducting polymer is the capability to switch the redox state 
after polymerization. As illustrated in Fig. 1-1. Conducting polymer exist in oxidized state after 
the electrochemical synthesis, with positive charges on the backbone of the polymer chain. The 
oxidized state is essential for the conductivity of the polymer, meanwhile small charged anion 
dopant A- is electrostatically bond to the backbone of the polymer, restricting the diffusion of 
these dopants via any contact with external environment. Once sufficient reduction potential is 
applied to the polymer matrix, the polymer can be reduced to lose the positive charge on the 
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backbone. The equivalent effect of this reduction reaction towards the mobile anion dopant A- is 
an electrostatic force to push the molecule A- out of the polymer film, because the polymer exist 
in neutral state[101]. This intriguing feature of conducting polymer have been utilized to release 
bioactive molecules in the past. The delivery of Dexamethasone was one of the most popular 
applications due to the appealing idea of suppressing the inflammatory response to the neural 
electrode in a precise manner may improve the longevity of the high quality neural recording on 
MEAs[102, 103]. Releasing neurotrophic proteins to support the survival of neurons and 
possibly restore damaged axonal connections also received significant amount of investigation 
[104-107]. An interesting idea of molecularly imprinted conductive polymers with the capability 
of delivering an intrinsically exist neurotransmitter molecule and subsequently allow the polymer 
to be replenished by this specific neurotransmitter in the surrounding extracellular space also 
brings about the appealing possibility of unlimited number of drug release with single implanted 
device[108]. 
1.3.3 Use of conducting polymer in neural engineering 
One approach for improving the performance of implanted MEAs by altering the surface 
properties of the microelectrodes is the electrochemical deposition of conducting polymers[109]. 
The conducting polymer can benefit the MEAs by decrease the electrical impedance [109, 110], 
promote specific cell attachment [88, 90, 111], or release anti-inflammatory drug like 
Dexamethasone [102, 112]. The modification of microelectrode with the conducting polymer 
coating can drastically increase the surface roughness and lead to large effective surface area for 
charge transfer and molecular adhesion [22]. Recently, developing ultra-small MEAs have 
gained wide popularity due to the beneficial properties for alleviating tissue response caused by 
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the implant [86, 113, 114]. The smaller penetration profile of such devices also remarkably 
reduce the probability of severing the axonal connections of the target neural population thus 
preserve the quality of the extracellular signal even for high density recordings [115]. The 
surface impedance, however, were noticeably increased by the reduction of Geometric Surface 
Area (GSA) of these devices, and the impairment to impedance cannot be corrected by any 
electrode conductor material itself. Deposition of metal oxide (e.g. IrO2) or fuzzy metal (e.g. Pt-
Black) have been investigated as possible solution, but the they pose the threat of releasing heavy 
metal ions or even micro particles that will harm the implanted tissue [33], especially during 
mechanical agitation or electrical stimulation. The electrochemically synthesized conducting 
polymer PEDOT is known for good conductivity, tunable morphology as well as outstanding 
biocompatibility, thus is ideal for lowering the impedance of such small GSA electrodes [86, 
114]. Among the widely investigated PEDOT polymers for improving the performance of neural 
implants, polystyrenesulfonate (PSS) doped PEDOT demonstrated high performance for chronic 
neural recordings [116]. The benefit of incorporating large molecule dopants relies on the 
immobility of such molecules. With the multi-site electrostatic bond between PEDOT and PSS, 
the polymers remains in very stable structure for long period. Functionalized CNTs with large 
amount of negative net charge on the surface have demonstrated beneficial recording 
performance, extending the success of PEDOT to even larger increase of surface area by the 
morphology with nano features[95]. These benefits can be replicated with polymerizing PEDOT 
with small ionic molecules in a highly conducting ionic liquid environment as well. The 
ultrahigh surface area with hollow structures allow the high mobility small anion dopants to be 
quickly exchanged with any PBS or saline solutions thus pose no threat to the biocompatibility 
of the polymer[110]. 
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1.3.4 Conducting polymer and functional carbon nanomaterials 
Carbon nanotubes[117] and graphene[118] materials have been widely investigated for 
various applications including electronics, optics and medical engineering due to their unique 
mechanical, electrical and optical properties. Graphene is known to be the thinnest material 
composed of single sheet of tightly packed carbon atoms in honeycomb structure. The large two 
dimensional structure of graphene create unique physical properties not known to any other 
material. Carbon nanotubes (CNTs) are long wire structure of carbon items that can be viewed as 
rolled up graphene in single- or multi-layer structure[119]. CNTs are broadly known for the 
outstanding mechanical strength, electrical conductivity as well as chemical stability[120]. The 
application of CNTs have been recently expanded into the neural interface field[121]. The 
incorporation of CNTs into conducting polymers PPy [122-125] and PEDOT [94, 95, 126-128] 
have been demonstrated in previous literature and shown improved polymer properties such as 
electrical conductivity and stability. The CNTs can be utilized in neural engineering field for 
improve neural stimulation [94], recording[95], stimulation neurite outgrowth[129], promote 
stem cell neuron differentiation [130] and serve as substrate for neuronal attachment and 
growth[131, 132]. One of the most intriguing applications of CNTs as blending material during 
conducting polymer synthesis is the capability of incorporating high concentration drug 
molecules in the inner cavities as serve as a reservoir for replenishing polymers during controlled 
drug delivery, as demonstrated in Fig. 1-2. 
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.  
Figure 1-2 Electrochemical synthesis of PPy conducting polymer with Chronoamperometry 
technique. High concentration drug solution is first loaded into the inner cavity of functionalized multi-walled 
CNTs. The CNTs are then incorporated into the conducting polymer matrix as dopant during electrochemical 
polymerization. The drug molecules in the CNTs are sealed by the polymer to prevent leakage. Once the redox state 
of the conducting polymer is changed to delivery drug from the polymer, the drug molecules in the conducting 
CNTs immediately diffuse out and replenish the polymer for further drug delivery trials.  
1.4 EXTRACELLULAR STIMULATION AND BARREL CORTEX RECORDING 
Deep brain stimulation (DBS) for the treatment of Parkinson’s disease[133-136], 
epilepsy[50, 137, 138], essential tremor[139, 140] and dystonia[141, 142] have been extensively 
investigated due to the therapeutic potential and the effectiveness of the technique in treating 
patients. More recently, DBS have also demonstrated promising treatment effect for emotional 
disorders like depression[143, 144], obsessive compulsive disorder (OCD)[145, 146] and 
anxiety. The electrical stimulation depolarizes the membrane potential of adjacent neurons to 
cause generation of action potentials[33]. Recent in vivo two photon recording of large 
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population of neurons distributed in a broad spatial range also revealed the activated neurons are 
distributed sparsely [147]. This is possibly due to the activation of axons traveling near the 
stimulation electrodes are activated preferentially by the stimulation[148]. Theoretical model 
studies have revealed the importance of capacitive current in activating neurons[149]. So we 
chose prolonged cosine waveform with very low rising slope for the trigger of drug release to 
minimize directly generated action potentials. The simultaneous recording and stimulation or 
sequential switch between recording and stimulation also require delicate electrical circuit as 
well as algorithms to reduce the artifact and noise during switch as well as ensure the safety of 
recording [18, 150]. In this study, a simultaneous recording and stimulation paradigm with 
completely different grounding skull screws to isolate the stimulation and recording circuits was 
utilized to deliver the drug while recording. The artefact evoked by drug release trigger was in 
reasonable range without impacting the neural recording performance after the stimulation is 
terminated. 
The Layer IV of barrel cortex is the input layer of neural information from the thalamus 
to the cortex for further processing[151]. Direct mechanical stimulation of facial whiskers of rats 
generated reliable neural response in specific barrels that topographically represent the facial 
whiskers [152, 153]. Iontophoresis studies with NMDA and AMPA receptor blockers in the 
barrel cortex successfully elucidate the various contributions of NMDA and AMPA receptor to 
the different temporal component of the barrel cortex response [47]. However, due to the 
limitation of iontophoresis device on single channel or few channel recording at same location. 
The multi-channel simultaneous recording and pharmacological intervention with 
electrochemically controlled drug release may provide new insight to the neural network 
dynamics affected by different receptor agonist or antagonists. 
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1.5 OUTLINE OF THESIS 
Chapter one of the thesis focus on the quantitative analysis of drug release from 
PPy/CNT conducting polymer matrix with a double layer polymer preparation on PEDOT/CNT 
coating. Previous work had demonstrated the use of electrochemically released AMPA receptor 
antagonist CNQX to precisely modulate neural network activity pattern in hippocampal neuron 
culture [154]. But because of the extreme difficulty to directly quantify the target molecule, 
CNQX, or its analog molecule DNQX, the precise concentration of released drug molecule was 
mimicked by fluorescein molecule and the dynamics of fluorescein release was carefully 
characterized. The fluorescent microscopy technique provide the real time diffusion profile and 
the semi-quantitative information about the detailed trend of fluorescein release over 90 trials. 
With carefully selected drug release trigger parameters, the concentration of delivered 
fluorescein can be fitted by a two term exponential decay function. The further spectrometry 
measurement of fluorescein and DNQX release directly from the polymer film on a novel 
microelectrode array was combined with the model prediction of fluorescein concentration and 
yield a precise quantitative model of DNQX concentration from the conducting polymer matrix. 
Chapter two expand the scope of releasable drug molecules to another important class of 
neurotransmitters, zwitterionic charged molecules like GABA. GABA not only serve as the 
primary inhibitory neurotransmitter in the brain, but also plays critical role in neuron 
development. And GABA neuron abnormality underlies various neural network mechanisms of 
disorders such as schizophrenia [155, 156]. Electrochemically synthesized PEDOT/CNT/GABA 
film successfully delivered GABA molecules upon receiving drug release triggers and the 
released GABA molecule maintained its bioactivity for inhibiting neural networks. The 
incorporation of GABA molecules on the surface of PEDOT polymer not only remarkably 
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improved the survival of neural stem cells and differentiation ratio into neurons, but also 
facilitated the neuronal survival and neurite extension on the polymer. The precise concentration 
of released GABA molecule from microelectrodes was quantified with custom build 
microelectrode arrays. Quantification result indicate the GABA doped PEDOT film can 
spontaneously leach out GABA to possibly facilitate neural development and can be triggered to 
release higher concentration of GABA upon demand. 
Chapter three extended the application of electrochemically controlled release of DNQX 
to the in vivo neural network in layer IV of barrel cortex. Simultaneous application of electrical 
trigger signal and collection of neural recording on 4 x 4 acute Michigan probe was conducted 
with carefully designed experiment paradigm. Barrel cortex neural activity was topographically 
evoked with air puff to facial whisker with high precision and reliability [157, 158]. The 
application of DNQX molecule abolished the neural network firing for one to six seconds while 
the control triggers without doped DNQX did not alter the neural network activity. The 
electrochemically controlled release can modulate barrel cortex activity for more than 25 trials 
and the spatial extent of the drug effect is about 400 μm radius according to a well fit second 
order polynomial function of drug effectiveness index.  
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2.0  QUANTIFICATION OF ELECTROCHEMICALLY CONTROLLED DELIVERY 
OF NEUROCHEMICALS FROM MICROELECTRODE USING A FLUORESCEIN 
RELEASE MODEL 
2.1 ABSTRACT 
Conducting polymers can be formed electrochemically on neural microelectrodes with 
negatively charged molecules incorporated in the process. When reductive potential is applied 
onto the conducting polymer film, the polymer backbone loses some positive charge but still 
maintain conductivity while dopant molecules can be precisely released from the film. The 
electrical-chemical coupling of signal on microelectrode mimic the synaptic transmission of 
neurons, during which action potentials trigger the release of neurochemicals in a precise 
manner. Conducting polymers on microelectrode arrays can delivery neural transmitters and 
modulators for neural activity modulation which can be simultaneously recorded with co-
existing neurophysiology recording channels. To elucidate the application conditions of this 
novel drug delivery technique, concentration and effective range of released drug molecule is 
mimicked by fluorescein and quantitatively assessed in a real time imaging system. Drug 
delivery parameters were carefully evaluated to precisely determine the amount of released drug 
from neural electrodes. AMPA receptor antagonist DNQX (6,7-dinitroquinoxaline-2,3-dione) 
was selected to represent a class of negatively charged neuromolecules due to its direct impact 
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on the fast excitatory neural transmission. This system demonstrates a possible foundation for 
feedback suppression of neural network activity in a localized manner beyond traditional fluidic 
and neural stimulation techniques. With the ease of being incorporated in existing neural 
electrode arrays and the controllable spatial and temporal dynamics pattern of drug diffusion, this 
technology may find use in a wide range of research and therapeutic devices. 
  
2.2 INTRODUCTION 
Fundamental brain functions such as cognition, learning, and memory are executed by 
activities of many neurons that form intricate circuits [159, 160]. Multielectrode Arrays (MEAs) 
with the capability of recording from ensembles of neurons in vivo or in vitro have been 
developed to extract information from such neural activity [37, 161].  To aid the study of neural 
networks and examine the response of networks to external perturbations, neural modulation are 
often necessary to change the networks. The ideal bi-directional neural interface systems require 
highly localized precise neural modulation[48]. Such attempts include electrical 
stimulation[162], drug infusion cannulas[57], iontophoresis[54] and more recently, 
optogenetics[74]. However, limitations are observed with each class of neural modulation 
techniques including selectivity, types and precision of neural modulation. And in some cases, 
the ongoing neural modulation treatments abolish the capability of MEAs to record from targeted 
neural tissue in real time. 
To solve some of these problems, a technique has been developed by Simon et al. in 
which the conducting polymer PEDOT doped with polystyrene sulfonate (PSS) has been 
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fabricated into a micro device that functions as an ion pump[163, 164]. The device has 
demonstrated controllability to precisely delivery neurochemicals for certain applications. 
Unfortunately, the device requires complicated fabrication and is not capable of neural recording 
or stimulation. Thus, it is very difficult to integrate the device onto in vivo MEAs.  
The redox property of conducting polymers is utilized in this work as the basis of our 
method development. Conducting polymers can be electrochemically polymerized directly on 
surface of neural micro electrodes [88]. Negatively charged dopants can be reliably incorporated 
into the polymer matrix through electrostatic force because the synthesized conducting polymers 
possesses positive charges[125]. These dopant molecules can be immobile or releasable to 
encourage specific cell/surface interaction or regulate the local biochemical environment [88, 89, 
165-167].  Only when negative current is injected into the conducting polymer matrix, the 
positively charged polymer backbone is reduced and less positive charges remain on polymer 
backbone to maintain the dopant molecules, thus the dopants are released when the redox 
reaction is triggered by electrical stimuli[101]. This polymer based electrochemical release of 
drug molecules have been utilized in several prototypic systems in which chemical agents such 
as anionic salicylate, adenosine triphosphate (ATP), 2-ethylhexylphosphate (EHP), and naproxen 
have been incorporated into different polymers and subsequently released in a controlled fashion 
[168-171].  In vitro utilization of this technique on releasing neuro-chemical CNQX (6-cyano-7-
nitroquinoxaline-2,3-dione), an AMPA (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic 
acid) receptor antagonist from Polypyrrole (PPy) has been demonstrated to suppress action 
potential generation in hippocampal neural cultures in a localized and transient manner [154]. In 
this work, 6,7-dinitroquinoxaline-2,3-dione (DNQX) molecule, a very similar chemical analog of 
CNQX to antagonize AMPA receptor, was utilized as the bioactive drug molecule to release. 
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However, the loading and release capacity of DNQX releasing PPy coating is limited. One 
important feature of CNQX or the similar DNQX molecule as dopant molecule is the drastic 
increase of synthesized polymer impedance, resulting in very low deposition current because the 
voltage of reaction must be limited to prevent over oxidize. With CNQX or DNQX doped PPy 
film, the polymer can only form a very thin layer on electrode surface and almost act as an 
insulation layer. To solve this problem, previous work in our lab have demonstrated the 
remarkable property of functionalized CNT to serve as reservoir for drug release and 
significantly improve the drug loading capacity[125]. The incorporation of CNTs in conducting 
polymers can also improve both the strength and conductivity of the conducting polymers [172], 
which is important to develop stable and long-lasting conducting polymer based drug release 
systems. The high conductivity can reduce the threshold of the drug release stimuli and the 
mechanical strength may prevent the cracking and delamination of the polymer film [173]. CNTs 
serving as structural supplement in the polymers are large in size and essentially immobile inside 
the polymer, this allows the negative current stimulation to deliver the small drug molecules 
without unbinding CNTs from polymer matrix[125]. However, even with the facilitation of 
functionalized CNTs, the PPy/CNT/DNQX polymer still can only form a thin layer structure due 
to the hindrance of DNQX on the polymer electrical conductivity. So a novel approach was 
developed in this work where PEDOT/CNT layer is first synthesized on microelectrodes due to 
the mechanical stability, expanded three dimensional surface area and low impedance of this 
polymer. The CNT network inside PEDOT polymer provide excellent mechanical property, 
expanded surface area as well as decreased surface impedance compare to the Pt/Ir 
microelectrode. PEDOT on its own also demonstrated excellent electrical conductivity and 
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stability. Polypyrrole/CNT/DNQX film is synthesized on top of PEDOT/CNT film to maximize 
the capacity of releasable neural molecules. 
The precise concentration of molecules delivered has proven difficult to quantify due to 
the difficulty in determining the quantity of polymer redox reaction and the small molarity of 
molecules that can be delivered on microelectrodes. In this work, the PEDOT/CNT and 
PPy/CNT/Drug polymer composite for releasing negatively charged neural molecules has been 
developed and carefully characterized. PPy/CNT/Fluorescein film on PEDOT/CNT polymer is 
synthesized on microelectrode to model DNQX release quantity. The release profile and 
diffusion pattern of Fluorescein model molecule was visualized and semi-quantitatively assessed 
by fluorescent microscopy at very low concentration. A two term exponential decay function 
fitted the release trend of fluorescein with very high fidelity. Next double layer Fluorescein and 
DNQX release was quantified with spectroscopy technique and the result was applied to semi-
quantitative model fitting to precisely determine the release dynamics for both molecules. 
With the development and characterization of this conducting polymer based drug release 
method in vitro, our novel technique can be readily implemented on either neural recording or 
stimulation sites of MEAs and multi-modal modulation of neural networks with various species 
of neural modulators can be easily achieved. Manipulation of in vivo neural networks without 
interrupting extracellular recording of adjacent electrodes demonstrates the working range and 
efficacy of the system.  
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2.3 MATERIALS AND METHODS 
2.3.1 Materials and Electrodes 
2.3.1.1 Materials 
DNQX disodium salt was acquired from Abcam (MA) or Alomone Labs (Israel), Multi-
walled carbon nanotubes (mwCNT) was purchased from Nanoamor (TX) and was chemically 
functionalized with –COOH with previously reported method [125]. UV-curing fluorescent 
transparent optical adhesives NOA 63 was obtained from Norland Products Inc. (NV) 127um 
diameter Platinum/Iridium (Pt/Ir 9:1) wires were purchased from A-M Systems (WA). All other 
chemicals were obtained from Sigma-Aldrich (MO). 
16 channel microelectrode arrays for in vivo neural recording and drug delivery was 
obtained from Neuronexus (MI). The GSA of electrode sites on the probe was 704 μm2. The 
electrodes are arranged on 4 shanks with 4 electrodes on each shank. The site spacing on each 
shank is 100 μm and the shanks are 125 μm apart from each other. The sites expand a depth of 
300 μm, allowing all recordings to be performed within layer IV of barrel cortex. 
CNT were first sonicated in acid solution (1:3 HNO3 and H2SO4) for 2 hours rendering 
the inner and outer walls of CNTs hydrophilic [174, 175]. This treatment also opens the CNT 
ends and removes the heavy metal, consequently eliminates the toxicity of CNTs. Ultracentrifuge 
( Sorvall RC 6 plus, Thermo Scientific, PA) at 12k-19k rpm was employed to remove the 
residual acid from the CNT. After the pH of CNT solution is pH neutral, the CNT were first 
dried with a rotovap then completely heated and dried in oven at 50 oC. The CNT was stored in a 
vacuum freezer at -20 oC with desiccants. 
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2.3.1.2 Epoxy multielectrode array for drug delivery 
Custom build microelectrode arrays were fabricated with three Pt/Ir wires and UV-curing 
epoxy. The fabrication process is summarized as follows: three Pt/Ir wires were carefully aligned 
inside a 200uL pipette tip submerged in epoxy. The epoxy was first cured with UV light source 
for 5 minutes. Then the array was further consolidated by 5 minutes UV exposure on the side. 
Next, a razor blade was utilized to slice open the side and remove the pipette tip, exposing the 
epoxy embedded Pt/Ir array. The array was sawed to 1.5cm length followed by alumina particle 
electrode polishing kit (CH Instruments, Inc., TX) with particle diameter of 1 μm and 0.3 μm. 
During fluorescein release experiment, a layer of black non-fluorescent liquid electrical tape 
(Mcmaster-Carr, IL) was applied onto the surface of the epoxy array to absorb non-specific 
reflection light. 
2.3.2 Electrochemical synthesis and characterization 
2.3.2.1 Electrochemical deposition 
PEDOT/CNT films were first potentiostatic deposited using a FAS 2 Femtostat (Gamry, 
PA) onto electrodes. The deposition solution was consisted of 0.015 M EDOT monomer and 1 
mg/μL CNT dissolved in 1mL de-ionized water (DI H2O). The concentration of EDOT monomer 
was slightly higher than the soluble amount of EDOT monomer in water because CNT surface is 
capable of absorbing EDOT monomers, allowing higher concentration of monomer to be 
dissolved. 15 minutes of sonication with a probe sonicator (Q500, Qsonica, CT) was applied to 
the mixed solution in order to homogenize the CNT and EDOT monomers. The polymerizations 
were carried out in a three-electrode cell consisting of a platinum sheet counter electrode and 
Ag/AgCl reference electrode, 0.95 V was applied to the working electrode for 15 s to form the 
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film. After the synthesis of PEDOT/CNT, the electrode arrays were removed from the deposition 
solution with EDOT monomer and CNT, followed by complete DI H2O rinse to remove any 
leftover monomer or CNT, then carefully dried for at least 5 minutes the PEDOT/CNT film to 
stabilize and to prevent dilution of the second layer polymerization solution.   
Fluorescein or DNQX molecules were loaded into the inner cavity of functionalized CNT 
(1 mg/mL) by mixing CNT and drug for 10 minutes. Pyrrole monomers were added to the CNT 
suspension with drug and further sonicated for 5 minutes. Electropolymerization was carried out 
during which PPy film grew on the microelectrode array sites and the drug-loaded CNT were 
sealed by the polymer. Chronoamperometry was utilized to synthesize the PPy/CNT/fluorescein 
film on top of PEDOT/CNT substrate film. Chronoamperometry was selected for synthesizing 
PPy/CNT/fluorescein film to prevent possible over-oxidation of the conducting polymer. The 
deposition potential was carefully controlled at 0.75 V and the duration was 15 seconds. After 
the electrodeposition was complete, the array was rinsed with DI H2O to remove the residual 
deposition solution. Then the array was washed in 1X PBS solution with stirring for 30 minutes 
before the drug delivery quantification experiment was carried out. 
2.3.2.2 Film characterization 
The impedance spectrum from 10 Hz to 32 kHz and cyclic voltammetry measurements 
with a scan rate of 1 V/s and a scan range of -0.9 V to 0.6 V were obtained using an Autolab 
N128 (Metrohm Autolab B.V., The Netherlands) in 10 mM phosphate buffered solution (1X 
PBS). The characterization was carried out in a three electrode electrochemical cell including a 
platinum sheet as counter electrode and Ag/AgCl reference electrode. 
Microscopy images of the polished microelectrodes and the polymer coated electrodes 
were examined under a Zeiss fluorescent microscope (Germany). Scanning electron microscopy 
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(SEM) images of polymer deposition on microelectrodes were taken using a JSM 6330F SEM 
(Joel, Japan). A 5 nm layer of Pd was sputtered onto the electrode to improve the conductivity 
before the SEM and 5 kV was used for the SEM imaging. 
 
2.3.3 Quantitative analysis of drug delivery 
2.3.3.1 Semi-quantitative fluorescent imaging for fluorescein release 
The setup for semi-quantitative characterization of Fluorescein release is illustrated in 
Fig. 2-1B. PEDOT/CNT and PPy/CNT/Fluorescein coated microelectrode arrays were mounted 
onto an electrode holder controlled by a motorized three-axis micromanipulator (Siskiyou 
Instruments, OR) for fluorescent imaging. A fluorescent microscope (Leica, Germany) with a 
488 nm excitation light and a 510 nm emission light because Fluorescein molecules with this 
excitation and emission wavelength was utilized for the fluorescent imaging. A Uniblitz shutter 
was inserted between the lamp and microscope to precisely control the duration of fluorescent 
excitation light, in order to prevent possible excessive photo bleach of the fluorescein. A 
solenoid fluidic controller was used to switch on and off the 1X PBS perfusion and vacuum 
suction simultaneously. The DAC output of a Digidata digitizer (Molecular Devices, CA) was 
utilized to generate the cathodic leading cosine waveform with an amplitude of 1 V, 1.5 V and 2 
V to trigger the release of fluorescein from the film. The duration of the cosine waveform is 100 
ms, followed by a 200 ms, half amplitude reverse polar charge balancing phase, accommodating 
for the conventional in vivo neural stimulation scheme to prevent tissue damage from injecting 
net charge. A fast CCD camera was used to record a series of tiff images at 10Hz for semi-
quantitative characterization of the Fluorescein release dynamics. The synchronization TTL 
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signals in the system is generated by a master 8 (A.M.P.I., Israel). The timing schematics of 
quantifying Fluorescein release is illustrated in Fig 2-1A. The PBS perfusion for 15 seconds is 
executed at the beginning of each drug delivery trial, ensuring the precision of the 5 seconds 
baseline fluorescent intensity imaging immediately following PBS perfusion. Then the 
fluorescent shutter is turned on and the camera imaging start at the same time. The PBS flow is 
completely stopped at 15 seconds to ensure a natural diffusion pattern of the Fluorescein 
molecule after the electrical trigger. Drug release electrode is stimulated with the drug delivery 
trigger 5 seconds after the camera start to take baseline measurement. Another 10 seconds of 
drug releasing electrode were captured to quantify the Fluorescein release and diffuse pattern. 
The microscope light source is controlled by a remotely switchable shutter to minimize the 
duration of applying fluorescent excitation light. Each drug release experiment is 30 seconds 
long in total duration. The fluorescent shutter is then turned off and 5 seconds inter-trial interval 
is used to save the fluorescent image series and clear the memory for the imaging software. The 
process to save image files and control the start of fluorescent image capture is automatic by a 
custom written Visual Basic (Microsoft, WA) script for directly interfacing with mouse, 
keyboard and software control. 90 Fluorescein release trials were conducted for each 
PEDOT/CNT PPy/CNT/Fluorescein coated microelectrode, in order to capture the full trend for 
the drug release dynamics. 
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Figure 2-1 Fluorescence imaging scheme for semi-quantitative measure of Fluorescein concentration. 
(A) Timing schematics of the Fluorescein release experiment. The drug release trigger is delivered at 20 s time 
point. (B) Setup schematics for Fluorescein release experiment, the green semi-ellipse represent the diffusion pattern 
of Fluorescein after been release. After PBS perfusion to remove excess Fluorescein, the drug release trigger is 
applied to release Fluorescein from the electrode on Epoxy array, the black dish represent the conducting polymer 
coated on the cross section of the Pt/Ir electrode. The counter electrode on the right side of dish is an uninsulated 
Platinum wire with sufficiently large surface area compare to the working electrode.  
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2.3.3.2 Spectrometry quantification of Fluorescein and DNQX release 
The drug release setup for spectrometry quantification of drug delivery was illustrated in 
Fig 2-2A. The setup allow most of the released drug to be accumulated in a very small volume 
thus a high concentration for the spectrometer measurement. A small Petri dish filled with DI 
H2O served as a moisture chamber to prevent excessive evaporation of drug release solution. A 
glass slide with hydrophobic surface was utilized as the substrate for drug release quantification. 
After the moisture maintaining petri dish, the slide and the platinum wire counter electrodes are 
positioned, 60 μL of PBS is added on top of the slide covering the platinum wire and form a 
liquid bubble under the surface tension. The drug release electrode is carefully positioned with a 
helping hand or micromanipulator to be submerged in the liquid bubble without touching counter 
electrode or the slide surface. 1.5 V drug release waveform was applied to the electrode for 45 
times to replicate the exact same amount of Fluorescein release observed by fluorescent 
microscope quantification experiment. The cosine drug release stimulation was carried out by 
FAS2 Femtostat (Gamry, PA).  After the drug release trigger was applied, repetitive pipette was 
utilized for gently homogenizing the drug release solution. 50 μL of release solution was then 
extracted from the liquid bubble and measured in a 96 well fluorescent plate for the 
quantification of analyte. The quantity of Fluorescein in this solution is used as the basis to 
calculate the total Fluorescein release in the 60 μL solution. Fluorescent spectrometry with 
excitation wavelength of 488 nm and emission wavelength of 510 nm was utilized to quantify 
the amount of released Fluorescein in the solution. 
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Figure 2-2 Quantify accumulated drug release amount with small volume drug delivery. (A) The drug 
release setup to precisely measure the drug release quantity in a very small volume PBS liquid bubble preparation. 
The PBS liquid bubble is maintained on the surface of a hydrophobic slide so the surface tension maintain a 
sufficient height of liquid bubble that enough distance is kept between the working electrode and the slide. The slide 
is placed directly on top of a petri dish so the local environment humidity around drug release PBS bubble is 
maintained at a high level. During the drug release experiment minimal amount of evaporation volume loss is 
observed from the liquid bubble. The custom build microelectrode array and the counter electrode Platinum wire are 
both positioned with a solder station. 
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The same drug release procedure was applied to DNQX coated bi-layer conducting 
polymer film and UV absorbance at 248 nm was utilized to quantify the amount of DNQX in the 
released solution.  
Due to the extreme low quantity of Fluorescein molecules released by microelectrode 
during each trial, the 90 trial concentration of fluorescein was divided into two accumulative 
amount for quantify. Trial 1-45 consisted the first release amount and trial 46-90 consisted the 
second release amount. Despite the extremely small amount of analyte present in the release 
solution, a detectable concentration of Fluorescein or DNQX was observed in the solution. 
2.3.4 Data analyses and statistics 
All digital image analysis was done by custom written MATLAB (Mathworks, MA) 
scripts. The fluorescent image was first loaded into MATLAB memory, an average image 
intensity over the whole period of the drug delivery was calculated as the static baseline image 
and subtracted from the whole image series. At the peak drug release intensity, a two-
dimensional Gaussian function is fitted to the image intensity in order to estimate the center of 
the Fluorescein release. Only the fluorescent intensity change within 100 μm diameter from the 
center of release was calculated for quantification purpose in order to better mimic the semi-
sphere diffusion profile of the Fluorescein.  
The fluorescent intensity of the image before the drug release trigger was subtracted from 
the maximum fluorescent intensity of the image series in order to calculate the fluorescence 
change. The change represent the semi-quantitative amount of Fluorescein released during this 
trial. For each release electrode, 1 V, 1.5 V or 2 V cosine stimulation was applied for 90 
Fluorescein release trials in order to monitor the drug release dynamics at this particular voltage. 
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A two term exponential function was fitted to the drug release intensity change over trials to 
directly compare the underlying redox quantity of each voltage condition. 
2.4 RESULTS 
2.4.1 Synthesis and characterization of bilayer drug loaded coating 
2.4.1.1 Fabrication of photopolymer Pt/Ir array  
To fabricate a low cost custom electrode array for electrochemical characterization and drug 
delivery quantification directly on top of a microelectrode, three 127um diameter Pt/Ir wires 
were embedded in a UV-curing optical adhesive photopolymer material. Pt/Ir wires were 
selected because of the wide acceptance of this class of inert metal alloy as the suitable neural 
stimulation and recording materials.  Different types of epoxy materials were compared for the 
potential use of insulating the Pt/Ir wire, the most important limitation is the auto-fluorescence of 
the epoxy material itself when directly excited by 488 nm wavelength, the working wavelength 
of Fluorescein. The photopolymer employed in this study features a very low self-fluorescence 
and an outstanding light transmission performance in a very wide wavelength range. The one 
part UV-curing design of this photopolymer also avoid the gradual self-polymerization of multi-
parts mixing epoxy materials, thus provide more controllability over the fabrication process just 
by UV exposure. The photopolymer exhibits minimal volume change and excellent adhesion to 
metal surface, providing a very tightly sealed insulating layer directly on top of the Pt/Ir 
conductors (Fig. 2-3B). Compared to the surface area of microelectrodes embedded in the 
photopolymer insulator, the insulation cross section area is hundreds of times larger. The 
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handling of fabricated array during the polishing procedure is thus very easy compare to other 
techniques of fabricating microelectrodes with consistent surface area. Microelectrodes 
fabricated with this method demonstrated an even cross section surface with very smooth 
morphology and reliable impedance performance (Fig. 2-3B).   
2.4.1.2 Deposition and characterization of PEDOT/CNT 
Functionalized CNT is incorporated beneath the PPy/CNT/Fluorescein film to maximize 
the amount of Fluorescein molecules been released according to previous study [125]. As 
demonstrated in Fig 2-3A, incorporating Fluorescein molecule decreased the conductivity of the 
polymer film and result in very low current and poor growth of the film. Because these, poor 
drug delivery performance was observed from these films in preliminary experiments. 
In order to create an electrode substrate more suitable for coating Fluorescein or DNQX 
incorporated PPy/CNT film, PEDOT/CNT was first deposited onto the electrode surface. After 
the electrochemical synthesis of PEDOT/CNT, the electrode surface impedance amplitude 
decreased significantly from the original values in Fig. 2-3A, due to the expanded surface area 
and the excellent conductivity of PEDOT polymer.  The biggest decrease of impedance 
amplitude occur in the low frequency range from 10Hz to roughly 1000Hz. The typical 
impedance of interest for neurophysiology applications because of the frequency of extracellular 
action potential waveform frequency, 1000Hz, was also greatly impacted by the surface 
functionalization of PEDOT/CNT. Because the PEDOT/CNT polymer can greatly reduce the 
impedance of electrode and the direct current (DC) resistance, the polymer synthesis on 
microelectrode accelerates significantly when the polymerization process begins. 15 seconds of 
electrodeposition yielded a thick and uniform conducting polymer surface coating (Fig. 2-3C) 
without significantly impacting the geometric range surface area of the microelectrode (Fig. 2-
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3B). The edge of the conducting polymer matrix is as smooth as bare Pt/Ir electrode surface in 
Fig. 2-3B. Under SEM examination in Fig. 2-4B, an ultra-porous three-dimensional matrix of 
PEDOT-CNT is observed on the coated electrode, permitting the maximum amount of surface 
area to polymerize the subsequent PPy/CNT/Fluorescein film. The CNT outer diameter is 20-30 
nm. The CNT diameter is not visibly affected by PEDOT polymer. 
 
 
Figure 2-3 Characterization of PEDOT/CNT deposition on Pt/Ir microelectrode. (A) Comparison of 
impedance amplitude before and after PEDOT/CNT electrodeposition. (B) The smooth metallic surface texture of 
Pt/Ir wire cross section following the electrode polishing procedure. (C) The PEDOT/CNT polymer completely 
change the surface texture of the Pt/Ir electrode in comparison with the surrounding photopolymer insulation 
material.  Scale bar=100um. 
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2.4.1.3 Synthesis and characterization of PPy/CNT/Fluorescein on PEDOT/CNT  
The electrodeposition current of PPy/CNT/Fluorescein on top of PEDOT/CNT is 
markedly increased from the current of direct deposition on the surface Pt/Ir electrode (Fig. 2-
4A). The total charge during the electrochemical synthesis is about 40 folds increase from the 
single layer deposition. In Fig. 2-4A, the coating current of single-layer PPy/CNT/Fluorescein 
film exhibit a decrease trend after a short spiking due to capacitive charging during 
Chronoamperometry deposition, but the double layer PPy/CNT/Fluorescein shows a very clear 
increasing trend as deposition time become longer. The possible reason behind this phenomenon 
is that when the PPy/CNT/Fluorescein film is synthesized on top of PEDOT/CNT film, the 
effective electrode surface area is much larger than the uncoated electrodes, allowing 
significantly more charge to be passed Although the poorly conducting PPy/CNT/Fluorescein 
slightly increase the electrode surface resistivity per area, the effective surface area of the 
conducting polymer increase quickly as more polymer is synthesized due to the roughened 
texture. The overall consequence of the two competitive mechanism is determined by the 
dominant one. As the result indicate, the effective area increase is remarkably stronger than the 
surface resistivity increase. 
 The solubility of EDOT in H2O is relatively low compare to pyrrole, so the synthesized 
PEDOT will only form a very thin layer of polymer on the CNT surface due to the limited 
concentration of monomers. Fig. 2-4C demonstrated the surface morphology of 
PPy/CNT/Fluorescein film grown on PEDOT/CNT under SEM. Although the CNT morphology 
in the SEM image is slightly affected by the surface adhesion of PPy polymers in Fig. 2-4C, the 
PPy/CNT/Fluorescein film is still capable of maintaining a very porous structure with large 
surface area to volume ratio. 
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Figure 2-4 Synthesis and characterization of PPy/CNT/Fluorescein polymer on Pt/Ir and 
PEDOT/CNT surface. (A) Chronoamperometry deposition of PPy/CNT/Fluorescein on Pt/Ir and PEDOT/CNT, the 
current on top of PEDOT/CNT film is markedly increased from the direct synthesis current on Pt/Ir. (B) SEM image 
of PEDOT/CNT substrate layer demonstrated very expanded bird nest like structure with three dimensional 
structures to facilitate the growth and adhesion of PPy/CNT/Fluorescein polymer. (C) SEM image of 
PPy/CNT/Fluorescein bi-layer polymer composite. The surface texture of PEDOT/CNT is replaced with 
PPy/CNT/Fluorescein, indicated by the more visible polymer morphology on the surface of CNT. (D) Cyclic 
Voltammetry characterization of single layer and double layer PPy/CNT/Fluorescein coating. (E) Impedance 
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amplitude of PPy/CNT/Fluorescein on PEDOT/CNT and Pt/Ir measured in the frequency range between 10 Hz and 
100000 Hz. 
 
Cyclic voltammetry (CV) measurement of redox current on differently prepared single-
layer and double-layer PPy/CNT/Fluorescein polymer also revealed very different performance 
of the polymer. The double layer conducting polymer exhibit a much larger current in the CV 
measurement, with prominent reduction peak around -0.6 V. The drug release trigger voltage 
was all designed to be much larger than the reduction voltage of PPy, allowing rapid shift of the 
PPy redox state during the drug release trigger. The cosine waveform for releasing drug is only 
100 ms in duration in order to minimize the net charge and tendency of DC like tissue damage. 
But the high amplitude compensate for the short duration of the waveform as demonstrated by 
successful Fluorescein delivery. The low impedance demonstrated in Fig 2-4E is also a clear 
benefit for the double-layer polymer preparation. With the same driving voltage, the current on 
low impedance electrode is much higher than high impedance electrode. The double-layer 
polymer film impedance at 10 Hz is almost 10 times lower than the single-layer polymer. This 
impedance reduction effect of bi-layer approach is most prominent at low frequency range that is 
most suitable for the frequency of our drug delivery cosine waveform. 
2.4.2 Fluorescein release quantification 
2.4.2.1 Electrically controlled delivery of Fluorescein 
The setup to quantify fluorescein release dynamics is illustrated in Fig 2-1. The flow of 
PBS can remove residual Fluorescein molecule from previous release trial and spontaneous 
diffusion, thus in the timing scheme of Fig 2-1A, the PBS flow was conducted immediately 
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before the imaging. The delivered drug quantity is related to the intensity difference before and 
after the drug delivery trigger. The drug release trigger is represented by the red vertical line 5 
seconds after the camera start to record baseline image as represented by Fig. 2-5B. Then an 
immediate increase of fluorescent intensity is observed following the electrical trigger. The 
concentration of Fluorescein around the drug release electrode was highest immediately after the 
drug delivery trigger and gradually decrease. In Fig. 2-5A, the drug release quantity is 
represented by subtraction of frame 1 intensity from frame 2 intensity, and in Fig. 2-5B, the 
quantity is the maximum intensity after the red line subtracting the intensity before red line. 
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Figure 2-5 Fluorescent intensity in one Fluorescein delivery trial.  (A1-5) Representative frames of the 
drug delivery and diffusion quantification process. The microscope was focused 20um below the electrode surface 
so the focal plane better represent the semi-sphere diffusion pattern of Fluorescein. In frame 1 the coated electrode is 
in black due to the optical absorption of CNT in the polymer matrix. Frame 2 represent the Fluorescein release 
process immediately after the drug delivery trigger. The Fluorescein was driven out from the conducting polymer 
due to the electrostatic force caused by polymer backbone reduction. From frame 3 to 5 the Fluorescein is clearly 
diffusing away gradually from the center of drug delivery. (B) The quantification of fluorescent intensity around the 
drug delivery electrode, with 100 μm radius from the center of a two-dimensional Gaussian function estimation of 
highest fluorescent intensity. The fluorescent intensity was highest following the drug release trigger and start to 
decay but maintained a relatively high concentration for a long period. 
 
2.4.2.2 Exponential decay model of Fluorescein release quantity 
The semi-quantitative measurement of Fluorescein release amount was conducted 
repeatedly for 1V, 1.5V and 2V. The result from different electrodes are illustrated in Fig. 2-6. In 
Fig. 2-6A, the drug delivery quantity trend for three voltages are summarized. The drug release 
quantity is positively correlated with the amplitude of the drug release stimulation. The drug 
release quantity at 1 V is significantly lower than 1.5 V and 2 V, indicating the amount of 
reduction reaction triggered by each stimulation amplitude is not linearly related to the applied 
potential.  
𝐶𝐹𝑙𝑢𝑜 = 𝑎 ∗ 𝑒
𝑏 + 𝑐 ∗ 𝑒𝑑                                       Eq. (1) 
The first 5 drug delivery trend is drastically different from the continuous trend 
afterwards, with much higher internal error as well. Physical adsorption of drug molecule 
contribute significantly to this phenomenon. Adherence force between the adsorbed molecule 
and the conducting polymer CNT matrix could vary drastically, so the PBS washing can only 
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partially remove the excess molecules. The drug release trigger is capable of removing the 
majority of these molecules in the first few release trials so the following quantity is only 
affected by the drug release reduction reaction and the drug molecule diffusion gradient in the 
matrix. In this experiment, the 1 V drug release quantity and the 2 V drug release quantity have 
very different dynamic range for the imaging requirement. For 1 V characterization the camera 
was set at higher multiplication gain to reduce the systemic error from internal thermal noise. 
The 2 V experiment was conducted with lower multiplication gain in order to prevent the camera 
from saturation. The inter group error between different electrodes is very low and was 
maintained across the trials. Only 2 V group displayed a relatively high variance possibly due to 
water hydrolysis that distort the fluorescent intensity quantification process. In the modeling 
process the first 5 trials of each group was removed to reduce the random error caused by 
different physical adsorption of molecules, the drug release quantity of 1.5 V and 2 V group both 
demonstrated a slight increase in fluorescent intensity at the beginning of the release trials, 
possibly because the dopant anion for surface polymer was replaced with PBS molecules during 
previous washing step, and the stimulation can replenish the surface with higher concentration of 
fluorescein from internal reservoir than the initial surface fluorescein concentration diluted by 
PBS.   
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Figure 2-6 Fluorescent intensity trend for different release conditions can be modeled with two term 
exponential decay function  (A) Fluorescent intensity change over trials for different drug delivery voltage groups, 
n=5 for 1 V group, n=5 for 1.5 V group, n=6 for 2 V group. The 2V group displayed larger variability during 
quantification possibly due to small amount of water hydrolysis formed air bubbles in some trials, interfering with 
the quantification. 2 V drug release trigger delivered the maximum amount of Fluorescein molecules, and the 
amount decrease with reduced voltage. (B) 1 V Fluorescein release group can be modeled by two term exponential 
decay function in Eq. (2). The goodness of fit is 0.99823. (C) 1.5 V drug release amount modeled by Eq. (2) 
function yield a goodness of fit value 0.99763. (D) 2 V drug release amount model yield a goodness of fit value 
0.99702. All three groups are well modeled by two-term exponential functions.   
 40 
2.4.3 Spectrometry quantification of Fluorescein and DNQX 
2.4.3.1 Quantification of accumulative Fluorescein release 
The semi quantitative assessment of drug release amount from fluorescence microscope 
follows a smooth and predictable pattern. However, the absolute quantity of Fluorescein 
molecules cannot be determined with this method because precise standard solution fluorescent 
intensity cannot be measured with the fluorescent microscope. The drug release process form a 
semi-sphere diffusion situation of Fluorescein with higher concentration in the center of 
diffusion. But a Fluorescein concentration function curve can only be drawn from a uniformly 
distributed concentration of molecules. So a spectrometry measurement of the Fluorescein 
concentration is preferred to quantify the amount of drug release and compare with known 
Fluorescein concentrations.  Due the extremely small size of our microelectrode drug delivery 
setup, the amount of Fluorescein delivered with a single release trial is below the detection limit 
of spectrometer measurement. Instead the accumulative Fluorescein release amount was chosen 
to quantify. If the low concentration of Fluorescein is evenly distributed in a relatively large 
volume and we have to sample a small volume of solution for spectrum measurement, the result 
will approach the PBS baseline value and suffer from high systemic error. So a very small 
volume drug release system is designed, with a total release volume of 60 μL and a measurement 
volume of 50 μL. The accumulative Fluorescein release amount for released trial 1 to 45 and 46 
to 90 are illustrated in Fig. 2-7A in comparison to the PBS baseline measurement. The 
fluorescent intensity emitted by the drug release solution clearly exceed the value of PBS, 
ensuring the relatively low contribution of systemic error from the spectrometer. To verify the 
trend predicted by the fluorescent microscope method, the quantity ratio from model predicted 
first and second 45 trials are calculated and compared to the measured ratio. The first 45 trials 
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were used as the basis of calculation because it yield a higher fluorescent intensity and was less 
affected by systemic error due to low analyte concentrations near detection limit. The single trial 
drug release quantity are not directly measureable with traditional drug delivery quantification 
techniques and can only be predicted by the back calculation from the accumulated release 
amount.  
 
 
Figure 2-7 Spectrometry quantification of Fluorescein release amount in 45 accumulated trials. (A) 
The Fluorescein quantity is directly measured by a function curve of known Fluorescein concentration and then the 
unit of amount is converted to the drug release quantity per surface area of electrode. The Fluorescein intensity 
accumulated in the first and second 45 trials are both detectable with the spectrometer. For the second 45 trials, the 
accumulated Fluorescein quantity measurement is directly compared to the value predicted by the first 45 trails and 
the modelled drug release trend. The comparison yield a high similarity. This is a clear confirmation of the model 
prediction performance. (B) With the quantity measured in the first 45 accumulated trials, the model can predict 
drug release amount during every single drug release trial. The Fluorescein release quantity can reach maximum 
value of 0.04 μg/cm2. By the end of the 90 drug release trials, the Fluorescein release is only 0.005 μg/cm2.  
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2.4.3.2 Quantification of accumulative DNQX release 
Another AMPA receptor antagonist, DNQX can directly affect neural network activity by 
suppressing the action potential generation mechanisms of neurons. The release of DNQX could 
be a valuable tool to control epileptic activity of local neural network or understand the spiking 
mechanism under the symptoms of other neural disorders. The trend for DNQX release quantity 
change is not measurable due to the low detection sensitivity of spectrometer to the UV 
absorption measurement. Only DNQX molecules with high concentration can be measured by 
the UV absorbance. So the release trend of DNQX molecules can only be predicted by the 
Fluorescein molecule. The model predicted a DNQX concentration very similar to the measured 
concentration for the second 45 drug release trials. Because Fluorescein quantification clearly 
confirm the model performance, this model and measurement similarity is a good indication that 
the drug release dynamics trend of Fluorescein molecules and the DNQX molecules are very 
similar to each other. Although the charge, molecular weight, solubility and other properties of 
the two molecules are very similar to each other, this is one of the first experiment result to 
justify the use of carefully selected fluorescent molecules for mimicking the drug release 
behavior of other molecules. It is important to note despite the similarity in the ratio of the first 
and second 45 accumulated drug release trials  between the two different drug molecules, the 
absolute quantity of released drug is very different between the two. DNQX molecules can be 
released up to a very high concentration compared to Fluorescein molecules. This phenomenon 
indicates although the drug release polymer matrix may display similar release dynamic process 
with the same type of electrical stimulation triggers, the release quantity may heavily depend on 
other factors such as the dopant concentration in the polymer. The similar release dynamics 
indicate the mobility of drug molecule from internal structure to the surface release reservoir 
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may behave similarly between different molecules. This mobility of molecules from interior to 
the surface of polymer could be viewed as concentration gradient driven diffusion, fluorescein 
and DNQX displayed similar diffusion constant in the process. 
 
 
Figure 2-8 Spectrometry quantification of DNQX release amount in 45 accumulated trials. (A) The 
DNQX quantity is measured by UV absorption of known DNQX concentrations and then the unit of amount is 
converted to the drug release quantity per surface area. The DNQX quantity accumulated in the first and second 45 
trials are both detectable with the spectrometer. The measured accumulated DNQX quantity in second 45 trials was 
compared to the modeled value. The high similarity in this comparison indicate the Fluorescein molecule is an ideal 
model system for mimicking the drug release behavior of DNQX.  (B) Model prediction of the 90 drug release trial 
quantity estimated by the accumulated drug molecula amount over first 45 release trials, every single drug release 
trial quantity is indirectly calculated from the model. The DNQX release quantity can reach maximum value of 4 
μg/cm2. By the end of the 90 drug release trials, the Fluorescein release is reduced to around 0.5 μg/cm2.  
 
 44 
2.5 DISCUSSION 
2.5.1.1 Benefit of double layer polymer on drug delivery 
The Chronoamperometry polymerization current of single layer and double layer 
PPy/CNT/fluorescein clearly indicate the film is difficult to polymerize even with the facilitation 
of CNT. The deposition current kept a downward trend due to the increase of polymer surface 
resistivity. However, the double layer polymer on top of PEDOT/CNT completely reversed this 
trend and allow a much large deposition charge for PPy/CNT/fluorescein film. After 
polymerization, the inner cavity of CNTs is filled with high concentration fluorescein, which acts 
as a reservoir for PPy[125]. During the controlled release of fluorescein from PPy film, the CNT 
reservoir replenish the fluorescein near the outer surface of conducting polymer. The 
PEDOT/CNT coating increase the surface area for deposition, decrease the surface impedance, 
and improves the polymer stability under long term electrical stimulation[128]. Additionally, the 
porous surface of PEDOT facilitate the deposition of PPy and allow more fluorescein to be 
incorporated in the polymer[96]. 
When electrically stimulation is applied to the PPy/CNT/drug film, some drug in the PPy 
film is released via dedoping. The electrical stimulation also causes a porosity increase due to 
actuation effect that allow drug inside the CNTs to diffuse into the PPy films and be released by 
the subsequent stimulus. The CNT selected for our study has outer diameter between 10-20 nm 
and inner diameter between 5-10 nm. The distribution of CNT inner diameter is also shifted 
towards larger size of 10 nm according to the manufacture. With these parameters this type of 
CNT has one of the highest inner/outer diameter ratio among all mwCNT. The higher inner/outer 
diameter ratio is equivalent of larger internal cavity size, yielding a larger drug contain reservoir. 
This inner/outer diameter ratio is even higher than the mwCNT utilized as reservoir in previous 
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study for releasing larger quantity of Dexamethasone[125]. The selection of single-walled CNT 
(swCNT) may further increase the inner/outer diameter of the polymer[176], however the 
functionalization of swCNT may cause the tubes to become very short segments due to strong 
chemical etching and sonication in the process. The functionalization process with concentrated 
Sulfuric and Nitric acid under strong sonication condition can cut the 10-30 μm long mwCNT 
down to 2 μm or less, while opening the end of the CNT for drug loading. 
For the second layer of conducting polymer film containing drug molecules, Polypyrrole 
is preferred compare to PEDOT. Another benefit brought about by PPy is the redox potential for 
PPy is much lower than PEDOT. Because the electrochemically triggered drug delivery requires 
reduction of conducting polymer backbone, PPy film can drive a large amount of drug delivery 
at low voltage amplitude around -0.34 V[102], but PEDOT can only be effectively reduced 
around -0.7 V[177]. The voltage measured by cyclic voltammetry in this work is not measured 
with saturated calomel electrode (SCE) so it is not a direct reflect of the PPy reduction peak. 
Baring the in vivo application of the technology in mind, the high reduction voltage amplitude of 
PEDOT endangers the neural tissue adjacent to the drug delivery electrode and may cause more 
side reactions such as water electrolysis when the polymer film is reduced for drug release. In the 
SEM image of PPy/CNT/Fluorescein, a porous structure of CNT and PPy is observed. The 
Fluorescein molecule release embedded in the conducting polymer matrix has a very large 
surface area to be released from. Furthermore, the hollow region between CNTs allows the 
polymers embedded deeper in the matrix to be released once the electrostatic force to hold the 
drug molecule is removed by the drug release trigger voltage. 
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2.5.1.2 Fluorescein model of DNQX release dynamics 
  The small fluorescent molecule Fluorescein was utilized as co-dopant for the synthesis of 
PPy/CNT/Fluorescein film, in order to mimic the drug release behavior of the neuroactive 
molecule DNQX. The Fluorescein molecule is suitable for several different reasons. Both types 
of molecules have two net charges per molecule in their disodium salt form. They have similar 
molecular weight (state what the weights are here) and good water solubility (state what the 
solubility is for each).  
The spectrometry detection limit of DNQX can only reach 0.16 μM while for Fluorescein 
the detection limit is 0.44 nM. Direct measurement of DNQX release from microelectrode has 
proven to be difficult as the concentration is below the detection limit of UV absorbance 
measurement. On the other hand, Fluorescein can be detected with better sensitivity. 
Furthermore, direct visualization of Fluorescein release provides an excellent model system to 
visualize the diffusion profile of DNQX following the electrically triggered release from the 
conducting polymer film. The fluorescent imaging setup can detect fluorescent intensity to a very 
low concentration due to the sensitivity of the Charge-coupled device (CCD) camera. Although 
the imaging intensity of the recorded fluorescent strength cannot be directly viewed as linearly 
related to concentration of fluorescein in most cases, in our case the estimation of concentration 
from the fluorescent intensity is justifiable. In the illustration of our setup, the flow chamber has 
a thin layer of solution in between the working electrode array and the glass coverslip at the 
bottom of the PBS perfusion chamber. The representative size of the conducting polymer film on 
microelectrode is not drawn to ratio compare to the whole system but instead was exaggerated 
for the purpose of viewing. With the small size of the microelectrode, the glass coverslip and the 
surface of the epoxy array can both be viewed as infinite in size. In this type of system the 
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diffusion of Fluorescein is mostly constricted to horizontal direction rather than vertical 
direction, leading to reduced out of focus light intensity. Direct characterization of conducting 
polymer film on microelectrode and quantification of drug delivery are essential to future 
application of the drug delivery technique for several important reasons: first, the synthesis of the 
exact same conducting polymer film on macroelectrodes are more difficult than on 
microelectrodes, with a lower current density for electrochemical deposition; second, the 
uniformity of electrochemically synthesized conducting polymer on macroelectrodes is typically 
much worse than on microelectrodes; third, the polymer thickness to geometric surface area 
(GSA) ratio of conducting polymer on microelectrodes are much higher on microelectrodes even 
with the same thickness of polymer film, requiring the consideration of edge surface area 
expansion effect and the three-dimensional micro structure of the polymer; fourth, the direct 
impact of conducting polymer on the electrode surface morphology and impedance is drastically 
different on microelectrodes and macroelectrodes, leading to poor correlation between the drug 
delivery quantity of the two classes of electrodes.   
2.5.1.3 Model prediction of Fluorescein release trend 
The drug delivery process demonstrated a two phase dynamic process due to two 
different mechanisms determining the amount of released drug. The first phase occur on the 
outer surface of conducting polymer film, which is in direct contact with PBS solution for ion 
exchange. The releasable Fluorescein quantity  of this phase is determined by the total 
Fluorescein near the surface of the polymer. The second phase involves the replenishment of this 
surface release amount. During each release, the Fluorescein near polymer surface is quickly 
depleted, generating a very high concentration gradient for internal Fluorescein molecules to 
diffuse outwards. Because the internal polymer matrix have much larger volume compare to 
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polymer surface. Internal Fluorescein molecules could be driven out by the concentration 
gradient with a small decrease to the internal Fluorescein reservoir and the next concentration 
gradient. Consequently, the final quantity of drug release after sufficient trials should reach a 
steady state, when the surface release rate of Fluorescein and the internal replenish rate of 
Fluorescein are roughly equal. The model prediction is substantiated by the decay function 
because the different between later drug release trials are much smaller compare to the early ones 
due to the exponential decay function.  
2.5.1.4 Spectrometry quantification of accumulated Fluorescein and DNQX release 
The small volume of 1X PBS was chosen for drug delivery quantification in order to 
obtain a detectable concentration of analyte. However small release volume is challenging for 
several reasons. First, care needs to be taken to position the microelectrode to avoid damaging 
the electrode and the drug releasing coatings. Another factor is the evaporation of liquid volume 
in the process. Because the PBS bubble has to form a semi-ellipsoid shape during the drug 
release process, the surface area to volume ratio of the PBS bubble is massive compared to 
solution in a chamber when the liquid form a cylindrical shape and only the cross section is 
exposed surface area for evaporation. The difficulty is overcome by maintaining high humidity 
around the PBS bubble.  
The comparison of Fluorescein quantity during release trial 46-90 between modeled 
prediction and the spectrometry measurement confirmed the quality of the model. The DNQX 
release measurement and model prediction further consolidated this result. This is further 
consolidated by the similarity between the DNQX prediction and the measured concentration. 
Furthermore, due to the difficulty in direct quantification of DNQX quantity released from micro 
electrode with small surface area, our accumulative measurement of DNQX concentration is one 
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of the earliest result to directly measure the drug release quantity from microelectrodes. And the 
single trial release quantity predicted by the model is beyond the detection limitations of other 
quantification techniques for the same purpose.  
2.6 CONCLUSIONS 
PEDOT/CNT conducting polymer markedly improved the electrodeposition of 
PPy/CNT/Fluorescein polymer on microelectrodes. The double layer conducting polymer 
coating demonstrated excellent electrical property and stability and can be electrically triggered 
to precisely deliver Fluorescein molecule of specific concentration. Precise quantification of 
fluorescent intensity was achieved by a real time fast fluorescent imaging system and revealed a 
double-exponential decay trend for the delivered drug concentration at each stimulation 
amplitude. With 100 ms 1.5 V amplitude cosine waveform stimulation, the electrode can deliver 
Fluorescein up to 0.04 μg/cm2 and DNQX up to 4 μg/cm2.  The quantification result indicate the 
releasable DNQX amount is sufficient to directly impact neural network activity in vivo.  
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3.0  MODULATING NEURAL NETWORK ACTIVITY AND NEURONAL STEM 
CELL DEVELOPMENT WITH POLY (3,4-ETHYLENEDIOXYTHIOPHENE)/CARBON 
NANOTUBE/ Γ-AMINOBUTYRIC ACID  
3.1 ABSTRACT 
Conducting polymers can be electrochemically polymerized on neural recording 
electrodes with charged molecules incorporated as co-dopant. Upon electrochemical stimulation, 
the dopant molecules can be released from the composite film. This property of conducting 
polymer can be utilized to deliver small charged neural active molecules from the neural 
electrodes in a controlled manner. Γ-Aminobutyric acid (GABA) is the predominant inhibitory 
neural transmitter in the central nervous system. It plays important roles in neural network 
activity and neural disorder mechanisms. Furthermore, neural stem cell development and 
neuronal cell survival are also greatly affected by GABA. GABA molecule represents a class of 
zwitterionic drugs that are difficult to incorporate and release by conducting polymers. In this 
study, a controlled, local release system to deliver GABA to neuron and neural stem cell cultures 
is developed. The impediment of utilizing GABA molecule with conducting polymer Poly(3,4-
ethylenedioxythiophene) (PEDOT) is overcame by incorporating functionalized carbon 
nanotubes (fCNT) into the matrix. The resulting PEDOT/CNT/GABA film stability, drug 
loading capacity as well as electrical property were all enhanced by CNTs. The 
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PEDOT/CNT/GABA film supported neuron survival and promoted the neuronal differentiation 
of neural stem cells. Electrically reducing the polymer film released incorporated GABA 
molecules in a controlled manner. Neural network activity of in vitro neuron culture were 
abolished by released GABA from the PEDOT/CNT/GABA electrode. 
3.2 INTRODUCTION 
Agonist and antagonist molecules are frequently applied to in vitro and in vivo neural 
networks to elucidate the mechanisms of neural dynamics and the network basis of system 
behavior [178, 179]. For example, in vivo extracellular recordings was combined with micro-
iontophoresis of specific receptor agonists and antagonists to reveal the role of different 
glutamate receptor subtypes in the neural network activity of rat barrel cortex[47]. Specific 
modulation of dopamine and norepinephrine receptors also revealed receptor subtypes 
differentially involved in neuronal firing tuning in the prefrontal cortex during working memory 
tasks [180]. Implantable neural probes and in vitro neuronal cell culture dishes that integrate 
pharmacological manipulation with electrophysiological recording could become a preferred tool 
to impact such field[181, 182]. 
Conventionally, systemic administration[183], global perfusion[58], and micro-cannula 
infusion[57] have been the most commonly utilized methods of drug delivery in vitro and in 
vivo. These methods are efficient and simple to apply in the cases that require low spatial and 
temporal resolution. Advanced research, however, requires controlled delivery or chemical 
stimulation at the scale of a small neural networks or even single neuron. Pressure puffing and 
iontophoresis have been employed for such control of neural activity [184]. However, these 
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methods are generally limited to very few targets. Micro-fluid channels equipped neural 
electrodes were also fabricated to achieve simultaneous chemical perturbation and electrical 
recording [185, 186]. The recent development in such technique eliminated the requirement of 
extra positioning devices and improved the spatial resolution and repeatability of local drug 
delivery. However, such complex fabrication with the addition of the channels, pumps, and 
valves for drug delivery can lead to lower yield, higher cost and higher failure rate. Furthermore, 
the size of the device were inevitably increased, which is undesirable for insertion injury and 
host tissue reaction in vivo. It has also been demonstrated that when a volume of liquid is 
injected to the host, physical disturbance or even separation to the nearby neural tissue could 
often be expected, adding difficulties to interpret the neurophysiological observations. A PEDOT 
PSS based ion pump micro device technique has been developed by Simon et al. to solve these 
problems [163]. Cationic species and neurotransmitters have been electrically pumped to the 
target cell or tissue without fluid flow [163, 164] in such cases. Unfortunately, the device 
requires complex fabrication, and is not compatible with simultaneous neural recording or 
stimulation studies. Our PEDOT/CNT based technique recruit a different mechanism to release 
neurochemicals from the polymer coated microelectrode arrays, bypassing the major hindrance 
of the previously discussed drug delivery methods.  
Conducting polymers can be electrochemically synthesized directly on the surface of 
micro- or macro electrodes. The polymer backbones are oxidized in the process and have 
multiple positive charges, while the dopant molecules with negative charge are electrostatically 
bond to the polymer backbone to balance the net charge of the film. When reduction potential is 
applied to the polymer, a controllable amount of positive charges are removed by the reduction 
reaction, removing the electrostatic force holding dopant molecules. Thus the dopants are 
 53 
delivered in the polymer reduction process. This redox property of conducting polymers serves 
as the foundation of our technique. The system has been widely explored to delivery negatively 
charged molecules for modulating biological processes. For example,  Our lab has previously 
demonstrated the in vitro utilization of this technique to release CNQX (6-cyano-7-
nitroquinoxaline-2,3-dione), an AMPA (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic 
acid) receptor antagonist to suppress action potential generation in hippocampal neural cultures 
in a precise manner [154]. And the delivery of anti-inflammatory drug Dexamethasone has also 
been used in vitro and in vivo to reduce inflammatory cell and tissue response [94]. On the other 
hand, loading and release of zwitterionic and cationic molecules has been largely limited. But 
some efforts have been made to delivery dopamine molecules with electrochemically controlled 
redox reaction of conducting polymers[187].[188-190]. The incorporation of cations requires the 
incorporation of large immobile anions as polymer dopant, and the cations could electrostatically 
bind to the large anion molecules. Though the feasibility of these techniques were evaluated, 
further in vitro and in vivo investigation of the benefit of drug delivery system needs to be 
characterized.  
 
 
Figure 3-1 Polymerization of EDOT monomer. When oxidation voltage is applied to the 
electropolymerization solution, the EDOT monomer in the solution will be oxidized and form PEDOT polymer. The 
conjugated polymer exhibit positive charge on the backbone, allowing the electrostatic interaction between PEDOT 
 54 
and the anionic dopant molecule A. Only a portion of the monomeric subunit on the polymer chain is positively 
charged and the ratio of these charged monomeric subunit is termed doping level. High doping level correlate with 
more drug molecules to incorporate due to increase in net charge. In the process of this reaction protons are 
generated so the solution pH is affected by the quantity of reaction. GABA molecules in the aqueous solution are 
utilized as the dopant molecule A. 
 
Neuronal activities on various scales, from synaptic transmission to network oscillation 
and plasticity, are mediated by various types of receptors that can be specifically activated, 
inhibited or modulated by endogenous and exogenous molecules. For example, GABA is a major 
inhibitory neurotransmitter that plays critical roles in neural network activity and function[191, 
192]. GABA is also important for developmental plasticity of neuronal circuits [193, 194] and 
the GABA system abnormality is associated with many types of neural disorders. The study of 
different receptors involved in neural network activity requires pharmacological manipulations 
of these target receptors[56].  
However, electrochemically controlled released of GABA molecule is difficult because 
of the zwitterionic property of GABA. During electropolymerization of conducting polymer, the 
quantity of zwitterionic molecule to incorporate is low. And GABA molecule reduce the 
conductivity of the polymer, thus only very small amount of polymer with GABA can be 
synthesized before the film become semi-conductive or even close insulative. Furthermore, no 
direct spectrometry measurement can quantify the concentration of GABA molecule in solution. 
To bypass these difficulties, we utilized CNT as dopant to facilitate the polymerization of 
PEDOT. Meanwhile, the interior cavity of CNT harbor high concentration GABA solution and 
function as reservoir of GABA molecule to remarkably increase the quantity of GABA loaded in 
the polymer film. Next, an optimized OPA fluorescent reaction for quantification of amine 
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groups on GABA was utilized to indirectly measure the precise concentration of releasable 
GABA molecules. 
The proposed mechanism of GABA molecule delivery is based on the local polarization 
of small molecules and the acid deprotonation dynamics in the solution. When GABA molecule 
are present in water solution, the amine group can undergo protonation process and gain one 
positive charge while the carboxyl group can deprotonate and gain one negative charge to the 
molecule. So the process yields no net charge for the molecule. However due to the positive and 
negative charge on amine and carboxyl groups , respectively, the GABA molecule is polarized in 
aqueous solution. During the polymerization of the solution, we hypothesize the carboxyl end of 
GABA molecules with negative net charge can be incorporated into the conducting polymer film 
as dopant molecules. And another source of GABA molecules in the polymer is the interior of 
CNT reservoir because high concentration GABA solution was pre-loaded into the CNT and the 
CNT was immobilized and sealed with PEDOT. When GABA molecule on PEDOT backbone 
was released by electrochemical trigger, the CNT reservoir can replenish the polymer GABA 
molecule by concentration gradient[125].  
The polymer and CNT film doped with GABA molecule can not only deliver GABA 
molecule on demand to modulate neural activity, the trophic effect of GABA can also facilitate 
NSC and neuron growth on the polymer surface. NSC and primary neuron culture was seeded 
onto four types of polymers: PEDOT/PBS, PEDOT/CNT, PEDOT/GABA and 
PEDOT/CNT/GABA. The NSC and neuron cell densities was quantified from 
immunohistochemistry images. The ratio of NSC differentiation into neurons was quantified by 
counting cells with neuron beta III tubulin marker and cells with glial marker. The neurite length 
extension was quantified from the immunohistochemistry of primary neuron culture and was 
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utilized to compare the beneficial effect of various polymers. The four experiment groups clearly 
demonstrate the benefit of CNT, GABA as well as the interaction between the two dopants for 
the performance of PEDOT polymer. 
To demonstrate the GABA release from electrode, X-ray photoelectron spectroscopy 
(XPS) technique was utilized to analyze the surface element ratio change following 
electrochemical drug release triggers. The drug delivery stimulation reduced the surface ratio of 
GABA molecules, indicating the electrochemical reduction of polymer successfully delivered 
GABA molecules over trials. 
Bioactivity of released GABA molecule was assessed to validate the system can 
successfully be utilized for delivery of GABA molecules to modulate neuronal firing. In vitro 
neuronal cell culture was utilized to verify the neurophysiological effect of the GABA release 
conducting polymer. Due to the low cost and large quantity of neuronal cell cultures compare to 
direct neurosurgical interrogation of in vivo neural networks, the method was developed as an 
excellent testbed for early phase pharmacological and toxicological assessment of various 
reagents. High throughput electrophysiological recording can be applied to the neural culture on 
the microelectrode array surface for the duration of the cell culture experiment. So we applied 
the released solution from macroelectrode to in vitro culture of neural networks on 
microelectrode array to suppress the neural activity in the network. The released GABA 
molecules produced a similar neurophysiological effect compared to a known GABA solution. 
This experiment clearly indicate the GABA molecules delivered by the electrochemical 
technique maintained their biological activity. 
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3.3 MATERIALS AND METHODS 
3.3.1 Materials and Electrodes 
3.3.1.1 Materials 
The materials utilized to build microelectrode array using optical adhesives are described in 
chapter 1. The Pt/Ir wires were obtained from A-M systems (WA). The UV-curing epoxy (NOA 
63) was purchased from Norland Products Inc. (NJ). Multi-walled carbon nanotubes (mwCNTs) 
were obtained from Nanoamore (TX) and functionalized with carboxyl groups using previously 
described method. Deionized water (DI H2O) was processed by a Millipore Q water purification 
system (EMD Millipore, MA). All other chemicals are obtained from Sigma-Aldrich unless noted 
otherwise. The brief method for functionalizing CNT and manufacture the microelectrode arrays 
are described as follows: 200 mg CNTs were first sonicated in strong acid solution (33.3 mL 
HNO3 and 100 mL H2SO4). With the heat generated by mix the two types of condensed acid, the 
solution was sonicated for two hours for chemical reaction and breaking the CNTs down from 10 
μm to around 1 μm in length. Then the solution is placed on a hotplate (55 oC) for overnight. 
Afterwards the acid was gradually removed by repetitively wash the solution with DI H2O and 
separate by ultracentrifuge at 12-19k rpm. The microelectrode array with Pt/Ir wires embedded 
in the optical adhesive was prepared as follows: first three micro wires were aligned in the 
optical adhesive solution, then UV light was shined onto the solution to cause the adhesive to 
cure. Then the array was sawed down to 1.5 cm in length and polished with 1um and 0.05 μm 
electrode polishing kit. After each time the array is coated with conducting polymer and used for 
drug delivery experiment, the electrode was polished again with the same method to a brand new 
state. 
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3.3.2 Electrochemical synthesis and characterization 
3.3.2.1 Electrochemical deposition 
The electrochemical deposition solution is prepared as follows: 1 mg CNT is mixed with 5 mg 
GABA in 1 mL DI H2O to obtain high concentration drug solution with CNT suspension 
solutions. After sonicating for 5 minute with a probe sonicator (Q500, Qsonica, CT), 1.5 μL 
EDOT monomer was added to the solution to prepare for electrochemical deposition. 10 minutes 
of further sonication is applied to homogenize the solution for polymerization. On 
microelectrodes, the PEDOT/CNT/GABA and PEDOT/GABA polymer were synthesized by 
passing 0.95 V to the microelectrode surface in a three electrode setup. A platinum sheet 
electrode was used as counter and a AgCl coated Ag wire was utilized as reference electrode. 
After the polymerization, the electrode array was carefully removed from the electrochemical 
deposition solution, gently rinsed with DI H2O and then stored in a container with high humidity 
but not direct contact with DI H2O. The array was stored for up to one days before the 
electrochemical release quantification was carried out on the GABA release array. For cell 
culture experiments the conducting polymer was deposited onto gold sputtered plastic 
microscope coverslips (macroelectrode area: 0.38 cm2) using a Gamry Potentiostat. 
3.3.2.2 Characterization of polymer 
The impedance spectrum from 10 Hz to 32 kHz and cyclic voltammetry measurements with a 
scan rate of 1 V/s and a scan range of -0.9 V to 0.6 V were measured by an Autolab N128 
potentiostat/galvanostat unit (Metrohm Autolab B.V., The Netherlands) in 10 mM phosphate 
buffered solution (1X PBS). A three electrode electrochemical cell including a platinum sheet as 
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counter electrode and Ag/AgCl reference electrode was utilized to carry out the impedance and 
cyclic voltammetry measurement. 
Microscopy images of the polished microelectrodes and polymer coated electrodes were 
examined under a Zeiss fluorescent microscope (Germany). The image brightness was adjusted 
for each situation due to the drastic difference in contrast for each type of polymer. Scanning 
electron microscopy (SEM) images of GABA polymer on microelectrodes were taken using a 
JSM 6330F SEM (Joel, Japan). A 5 nm layer of Pd was sputtered onto the electrode to improve 
the conductivity before the SEM and 5 kV accelerating voltage was utilized for the SEM 
imaging. 
3.3.3 Evaluation of drug release and quantification of delivered GABA molecules 
3.3.3.1 XPS analysis of drug release 
XPS analysis of PEDOT/GABA films was performed with a K-Alpha XPS system 
(Thermo Scientific) equipped with a monochromated Al Kα source (1486.68 eV). The 
conducting polymer underwent up to 90 cyclic voltammetry stimulation to delivery GABA 
molecules. The structure of PEDOT and GABA are demonstrated in Fig. 3-2. One GABA 
molecule contains one nitrogen atom and no sulfur, while EDOT repeat unit in PEDOT 
molecules contains one sulfur atom but no nitrogen, therefore, N/S ratio can be utilized to 
quantify the molar ratio between GABA and EDOT unit in PEDOT and the N/S ratio decrease 
over stimulation trials would indicate the release of GABA from the polymer composite film. 
When GABA gets released, the phosphate ion in the PBS solution may be exchanged into the 
polymer film, which can be observed on XPS.  
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Figure 3-2 The chemical structure of PEDOT and GABA molecules.  GABA contains one nitrogen and 
no sulfur while PEDOT molecules have sulfur element but no nitrogen, therefore, nitrogen and sulfur element is 
utilized to quantify the molar ratio between GABA and EDOT unit in PEDOT. 
 
3.3.3.2 OPA assay for quantification of amine group 
The OPA reagent react with thiol group in 3-MPA and amine group in basic environment 
(pH 9-11) and form a fluorescent product. The excitation wavelength is 340 nm and the emission 
wavelength is 455 nm. This fluorescent emitting reaction is utilized as the main mechanism to 
quantitatively assess amines or amine containing compound in analytical chemistry. The 
selection of thiol reagent directly impact the stability of fluorescent signal over time due to the 
stability of fluorescent product molecule in Fig. 3-3. The OPA reaction duration was optimized 
to be 100 seconds in order to achieve a stable measurement. The concentration of OPA, 3-MPA 
and amine group of GABA follows the optimization of previously conducted HPLC 
experiments[195]. Mixture of 3 mM OPA and 9 mM of 3-MPA reagent in Borate Buffer 
Solution (BBS) at pH=9.3 was utilized. Preparation of OPA fluorescent reagent was fresh for 
each experiment and extra solution was stored in 4 oC for use up to three days. The spectrometry 
technique to detect drug delivery from epoxy microwire arrays was utilized to quantify the 
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GABA delivery from the microelectrodes. In brief, the microelectrode array was positioned 
carefully in 60 μL of PBS solution and stimulated with -1.5 V amplitude cosine waveform and 
20 μL of the release solution was collected for OPA and moved to 96 well plates. The three 
microwire electrodes in each array were shorted together for increasing the quantity of GABA 
delivery. From trial 1 to trial 60 the release were accumulated each 15 trials, yielding 4 samples 
to quantify. From trial 61 to trial 150 the release were accumulated by 30 trials so the reduced 
GABA concentration can be quantified with better signal and less systemic error. After all 
GABA solution was collected, 200 μL of OPA reagent was immediately added to the solution 
and 100 seconds were allowed for the OPA to react with 3-MPA and GABA. The fluorescent 
intensity was sampled for 30 seconds at 5 seconds interval and the average intensity for each 
well was used as the final fluorescent intensity for calculating GABA concentration.  
 
 
Figure 3-3 The chemical reaction to quantify amine groups in GABA. The OPA reagent react with thiol 
group on 3-MPA and the amine group in GABA molecule to form a stable fluorescent emitting derivative. The 
reaction serves as the basis to quantify amine groups in the solution. 
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3.3.4 Neural stem cell and neuron culture on GABA polymer 
3.3.4.1 Neural stem cell culture 
NSCs were isolated from the cortical tissue of E18 Sprague-Dawley rat embryos. The 
tissue was triturated in a Hank’s Balanced Salt Solution (HBSS, Sigma-Aldrich) solution 
containing GlutaMAX (1%, Invitrogen) and Penicillin-Streptomycin (Pen-Strep; 1%, 
Invitrogen). The tissue was allowed to settle and the supernatant was centrifuged to pellet the 
cortical cells. After resuspension in NeuroCult NS-A proliferation medium (StemCell 
Technologies) with recombinant human epidermal growth factor (EGF; 20 ng mL-1, Invitrogen), 
recombinant human basic fibroblast growth factor (bFGF; 10 ng mL-1, Invitrogen), Heparin (2 
mg mL-1; StemCell Technologies), and Pen-Strep (1%), the cortical cells were maintained at 
37°C for 3 d or until the formation of neurospheres was detectable. The cells were then passaged 
as necessary every 3-4 d and were used for assays within passages 2 to 4.  
For NSC experiments, the neurospheres were passaged to achieve a uniform suspension 
and seeded on prepared cell culture surfaces at a density of 150,000 cells cm-2. The seeded cells 
were maintained at 37°C in NeuroCult NS-A Differentiation medium (StemCell Technologies) 
supplemented with Pen-Strep (1%) in the absence of growth factors in order to induce 
differentiation. The culture medium was exchanged every 3 to 4 d depend on the cell density and 
the culture medium indicator. 
NSCs were seeded on the surface of the PEDOT films that were treated with PLO (20 μg 
ml-1in PBS, 1 h incubation) and fixed with paraformaldehyde (4%) at 7 d to assess 
differentiation. The samples were immunostained with markers for neurons (mouse monoclonal 
anti-β-III-tubulin, TuJ1; 1:500; Sigma-Aldrich), astrocytes (rabbit polyclonal anti-glial fibrillary 
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acidic protein, GFAP; 1:500; DAKO). The brief immunohistochemistry procedure is as follows: 
the cells were treated in blocking buffer (5% goat serum in PBS with Triton-X, 0.02%, for TuJ1 
and GFAP) for 20 min, then incubated in primary antibody for 2 h at room temperature followed 
by fluorescent secondary antibody (Alexa Fluor 488 anti-mouse or Alexa Fluor 594 anti-rabbit; 
Molecular Probes) for 45 min at room temperature. The cells were counterstained for nuclei 
using Hoechst 33342 (Invitrogen). 
TuJ1-immunoreactive cells and GFAP- immunoreactive cells were quantified to 
determine the extent of neuronal and astrocyte differentiation on each culture substrate (n = 3 for 
each). Each sample was imaged using a 20x objective and 10 random images were taken for 
quantification of neuronal differentiation ratio. Values were reported as the percent of 
differentiation by dividing the number of TuJ1 or GFAP cells by the total number of nuclei 
present in the image. 
3.3.4.2 Primary neuron culture 
PEDOT/PBS, PEDOT/CNT, PEDOT/GABA and PEDOT/CNT/GABA coated 
macroelectrodes were fixed to the surface of 24-well culture plates with Kwik-Sil (World 
Precision Instruments) and sterilized with UV light for 15 min. The polymer surfaces were 
washed with sterile PBS immediately afterwards. Cortical tissue was isolated from E18 Sprague-
Dawley rat embryos and treated with 0.025% Trypsin in a buffer containing 137 mM NaCl, 5 
mM KCl, 7 mM Na2HPO4, and 25 mM HEPES. Neurons were dissociated with gentle 
trituration and maintained in Neurobasal medium (Invitrogen, 21103-049) supplemented with 
B27 (Invitrogen, 17504-044), GlutaMAX (Invitrogen, 35050-061) and Antibiotic-Antimycotic 
(Invitrogen 15240-062). For neuron growth experiment, cells were seeded on GABA and control 
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polymer surfaces at a density of 100k cells per electrode and grown for 3 days. To measure the 
neurite length by preventing the formation of very long and interconnected neurites, neurons 
were seeded on the polymer surfaces at a density of 100k cells per electrode and grown for only 
24 h before fixation and immunocytochemical analysis followed by quantification of neurite 
length. 
3.3.4.3 Immunofluorescence staining and quantification 
Neurons growing on the polymer surfaces were fixed in 4% paraformaldehyde in PBS for 
15 min and washed with 2 minutes PBS soaking for several times. The cells were immersed in a 
blocking buffer (5% goat serum/0.2% triton-X in PBS) for 20 min followed by incubation in 
mouse monoclonal antibody against β-III-tubulin (TuJ1, 1:1000, Sigma) for 1 h. After washing 
in PBS, the cells were incubated in goat anti-mouse Alexa Fluor 488 (1:1000, Invitrogen) 
secondary antibody for 1 h, washed thoroughly in PBS several times. 
TuJ1-positive neurons were imaged using a fluorescence microscope. For each group, 10 
random 10x images were collected from each sample (n = 3). Neuron density was quantified by 
counting the number of TuJ1-immunoreactive cells that clearly display at least one neurite that 
measured longer than the width of the cell body. Neurite length analysis was performed using the 
NeuronJ plugin for ImageJ (http://rsbweb.nih.gov/ij/). Neurites extending from each neuron cell 
body were traced and measured, and the average neurite length was calculated and compared. 
3.3.4.4 Statistical analysis 
Statistical analyses of cell culture experiments were carried out in SPSS software. Student’s 
t-tests were utilized for comparison of two experimental groups. Statistical significance was 
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considered for p < 0.05 (*) and p < 0.01 (**). All data is presented as the mean (± standard error of 
the mean). 
3.4 RESULTS 
3.4.1 Synthesis and characterization of GABA loaded coating 
3.4.1.1 Electrochemical deposition and characterization 
The microelectrode array was coated with conducting polymer PEDOT/CNT, 
PEDOT/CNT/GABA, PEDOT/PBS and PEDOT/GABA. The performance of PEDOT/GABA 
and PEDOT/CNT/GABA is compared to demonstrate the beneficial effect of CNT in facilitating 
the loading and release of zwitterionic molecules. Because the carboxyl group of GABA with 
negative charge acts as dopant for PEDOT polymers but the positive charge of amine groups will 
interfere with GABA incorporation, the use of GABA as dopant molecule is difficult and may 
yield very small quantity. Thus the addition of CNT is critical to increase the quantity of GABA 
molecules in the reservoir. In Fig. 3-4A, the coating current for PEDOT/GABA polymer with 
and without CNT were directly compared. The coating with CNT exhibited an increased current 
for the Chronoamperometry deposition at the same potential, 0.95 V. The curve also 
demonstrated two modes, the first mode is the general decreasing in current similar to 
PEDOT/GABA, the second mode was the slight convex of current around 5 seconds. The convex 
structure was because the newly synthesized conducting polymer could increase the surface area 
at high rate and partially overcome the increase in surface resistivity. Although the coating 
current and total charge density for PEDOT/GABA deposition shows significance difference 
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without the CNT, the final impedance of the electrodes demonstrated in Fig. 3-4B is very similar. 
The polymer with CNT demonstrated lowered conductivity at high frequency range and higher 
conductivity at low frequency range. This difference in impedance amplitude spectrum is 
typically considered very small thus indicate the electrodes has very similar performance. The 
cyclic voltammetry measurement of the polymers yield very similar performance. The 
PEDOT/CNT/GABA polymer exhibit slightly increased overall charge storage capacity while 
the PEDOT/GABA polymer displayed a more prominent reduction peak for drug delivery 
reaction at -0.35 V. 
 
 
Figure 3-4 Morphology of GABA polymer with PEDOT and CNT. (A) The coating current comparison 
between PEDOT/CNT/GABA and PEDOT/GABA demonstrate the contribution of CNT to the electrochemical 
deposition of PEDOT polymers, the polymer including CNT exhibit much higher potentiostatic deposition current. 
Despite the downward trend of coating current for both types of conducting polymers, the deposition charge of both 
PEDOT/CNT/GABA and PEDOT/GABA reached sufficient amount to form a visible layer of conducting polymers 
and change the electrochemical characteristics of the electrode. (B) Impedance spectrum of PEDOT/CNT/GABA 
and PEDOT/GABA comparison between 10 Hz and 100000 Hz. The different between the polymer with and 
without CNT is very small. PEDOT/CNT/GABA polymer exhibit a slightly lower impedance value especially at 
low frequency range, this validate the CNT included polymer display less DC resistivity thus allow more coating 
current to form the polymer. (C) Cyclic voltammetry characterization of PEDOT/CNT/GABA polymer and 
PEDOT/GABA polymer between -0.9 V and 0.6 V. The scanning range was chosen to prevent water hydrolysis at 
large amount while maintain sufficiently low voltage to reveal the drug release reduction activity of the polymer. 
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The PEDOT/CNT/GABA polymer exhibit a slightly large current compare to PEDOT/GABA polymer while the 
PEDOT/GABA polymer displayed a more visible PEDOT reduction peak for drug delivery.  
 
3.4.1.2 Morphology characterization of GABA polymer  
The morphology of PEDOT/CNT/GABA and PEDOT/GABA was very different despite 
the similarity in the CV current and impedance spectrum. As demonstrated in Fig. 3-5B and E, 
the PEDOT/CNT/GABA film was thick and uniform, with a nanostructure feature size slightly 
larger than PEDOT/CNT compare to Fig. 3-5D. The polymer appears dark in color due to the 
absorption of light by CNT. Obvious deposition of PEDOT on the surface CNT was visible 
under SEM in Fig. 3-5E yet the hollow structure allowing ion mobility deep inside the polymer 
matrix maintained compare to PEDOT/CNT film. The polymer grew on the surface of the 
network of CNTs. This changes diameters of the nanotubes roughly 20-30 nm to around 50 nm. 
The hollow area in between individual CNTs are reduced as a consequence. In comparison, the 
PEDOT/GABA film in Fig. 3-5C lack the uniformity and thickness compare to PEDOT/CNT 
and PEDOT/CNT/GABA. The SEM morphology of PEDOT/GABA exhibited a cauliflower-like 
topography with spherical nanostructure on the surface. This less porous polymer matrix 
prevents the penetration of ions into the polymer film or the diffusion of deeply embedded drug 
molecules outwards. Due to the lack of CNTs in the PEDOT/GABA polymer to absorb light 
completely on the surface of electrode, the thinner polymer appears mostly clear with a different 
light refraction index. Thus the thickness difference of PEDOT/GABA across the surface of the 
microelectrode was clearly indicated by various darkness of the polymer coated regions. In both 
PEDOT/GABA and PEDOT/CNT/GABA cases the PEDOT polymer growth did not exceed the 
GSA of microelectrode itself, this addition of conducting polymer without impairment to the 
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electrode stimulation or recording spatial resolution is beneficial for interfacing with neural 
tissue.   
 
 
Figure 3-5 Morphology of GABA polymer with PEDOT and CNT. (A) Electrochemical deposition of 
PEDOT/CNT show a dark color appearance. The conducting polymer matrix expand slightly beyond the edge of the 
microelectrode. The difficulty for synthesizing PEDOT/CNT polymer is low so the PEDOT/CNT form a thick and 
uniform layer completely cover the surface of the microelectrode. (B) Incorporation of GABA into PEDOT/CNT 
polymer yield a very similar morphology compare to PEDOT/CNT only, the microelectrode was completely 
covered by a uniform layer of PEDOT/CNT/GABA polymer, allow the maximum amount of GABA molecules to be 
uniformly released from the surface of the electrode. (C) The PEDOT/GABA polymer without CNT demonstrated a 
completely different morphology due to the difficulty of electrochemical deposition. The uniformity of the polymer 
was undermined by the uneven distribution of charge deposition on the microelectrode surface. The center of 
microelectrode received more charge thus the polymer thickness and uniformity was superior compare to the edge of 
the microelectrode. (D) The microscopic texture of PEDOT/CNT under SEM examination. The polymer clearly 
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demonstrated an expanded structure with CNT visible on the surface of the matrix. Hollow area in between the CNT 
structure exist uniformly across the surface of the microelectrode, allowing the ionic exchange of the polymer matrix 
and solution penetrate to significant depth in the polymer. (E) SEM image of PEDOT/CNT/GABA polymer 
demonstrated a similar surface texture feature compare to PEDOT/CNT but the CNT polymer was clearly covered 
by PEDOT/GABA polymer. (F) Surface morphology of PEDOT/GABA observed under SEM illustrated a clearly 
different appearance. The morphology better resembles traditional conducting polymer such as PEDOT/PSS. The 
GABA molecules impede with the polymerization process so the polymer is only deposited as a thin layer on the 
electrode surface. The polymer exhibit a roughened surface than the bare metal electrode and shows cauliflower like 
surface patterns.  
 
3.4.2 Electrochemically controlled GABA release 
3.4.2.1 XPS characterization of GABA delivery on macroelectrodes 
Fig. 3-6A shows the XPS of PEDOT/CNT/GABA film before and after 30 cyclic 
voltammetry (CV, cycles of ramping voltage, -0.9 to 0.5V, 100 mV/s) stimulation. Comparison 
of the two XPS spectrum reflect the dynamic change of GABA, PEDOT and phosphate quantity 
on the surface of the conducting polymer due to the exclusive existence of nitrogen, sulfur and 
phosphor in the three types of molecules, respectively. Due to the presence of chlorine in the 
PBS solution, a chlorine peak was also observed at 30 cycles of CV drug release stimulation. A 
drug delivery trigger is typically composed of two phases, one is the negative reductive phase to 
reduce the positive charge on the polymer in order to electrostatically repulse the anion dopant 
molecules into the surrounding environment, and the second phase was reversed to balance the 
charge in order to reduce the potential harmful effect of the polymer to biological tissues. 
Another important reason for charge balance phase is the conjugate polymer with more positive 
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charges demonstrate better conductivity than the reduced polymers, thus to allow further 
stimulation to cause drug delivery, the film is preferentially oxidized to partially recover the 
conductivity. During the re-oxidation of the polymer, limited quantity of drug molecules are re-
absorbed into the surface due to the quick diffusion of the drug molecule, meanwhile the 
omnipresent PBS anions including phosphate and chlorine anions were incorporated into the film 
and was observed with XPS analysis. In Fig. 3-6B, N/S ratio was deduced from the XPS spectra 
indicating the molar ratio between GABA and the EDOT unit in the polymer matrix. After 
stimulated with 30, 60 and 90 CV cycles, the amount of GABA in the film consistently 
decreased, illustrated by the N/S ratio decreases in Fig. 3-6B. The reduction trend of N/S ratio 
follows a linear correlation indicated by the blue fitted curve in the plot. The linearity of the 
nitrogen content reduction reflect a rough trend for GABA molecule depletion in the polymer 
matrix. 
 
 
Figure 3-6 XPS characterization of PEDOT/CNT/GABA delivery. (A) The XPS characterization of 
PEDOT/CNT/GABA film. At CV cycle 0, the film exhibit prominent characteristic peaks for nitrogen and sulfur 
element. Due to the high surface ratio of GABA molecules when the film was first synthesized, the N/S ratio of the 
polymer is high according to (B). At 30 CV release cycles, the surface GABA molecules ratio is decreased, thus the 
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N/S ratio was decreased due to the exclusive presence of nitrogen in GABA molecule on the surface, while the 
phosphor characteristic peaks were present because the PBS anions exchange with the released drug molecules to 
balance the polymer backbone charge. (B) Quantitative N/S ratio characterized in various films following GABA 
delivery CV cycles. With the increase of CV cycles, the GABA quantity decrease gradually over trials, due to the 
consistency of sulfur in PEDOT backbone, the nitrogen atom is directly correlated with the total amount of GABA 
molecule on the surface of polymer. The N/S ratio of polymer film follows a decreasing trend demonstrated by the 
linear fit, with high linearity. 
 
3.4.2.2 OPA fluorescent reagent quantification of released GABA 
OPA reagent were prepared fresh before each GABA quantification experiment and is 
only used for up to 1 day after the initial mixture of the solution. The recipe was obtained from 
previously reported HPLC quantification method and was verified with known concentration 
GABA solutions. The selection of 3-MPA and the BBS buffer with pH=9.3 was optimized to 
yield a stable fluorescent derivative compound to quantify. The fluorescent intensity of OPA 
reagent reacting with GABA solution was very stable as indicated in Fig. 3-7A. The fluorescent 
intensity measured over 240 seconds was repetitive for each concentration. The result is depicted 
in Fig. 3-7B where the GABA concentration and the fluorescent intensity of OPA reagent was 
linearly correlated with very small variation across all concentrations. Fluorescence fluctuation 
of Fig. 3-7A also indicate the optimal technique for quantifying GABA concentration is to 
repetitively measure the kinetics of fluorescent intensity change over sufficient duration and 
calculate the average intensity of the solution, because the intensity variation of individual 
solution was obvious over time but only fluctuate around one stable value. Due to the stability of 
PBS blank control and 0.2 μM GABA solution, the quantification of lowest examined GABA 
solution can be precisely determined with time-lapse average of the fluorescent intensity. 
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Consequently, 30 seconds of measurement with 6 seconds interval between each value was 
utilized as the standard procedure to quantify the amine group concentration in the unknown 
drug delivery solution.  
 
 
Figure 3-7 The functional curve of OPA reagent detection of amine group. (A) Kinetic measurement of 
fluorescent intensity following the OPA reagent reaction with GABA solution yield a very stable measurement of 
low concentration of GABA solution. The curves are samples at 10 seconds interval for 250 seconds, the fluorescent 
intensity of each solution remained stable. (B) The fluorescent intensity linearly correlate with the known 
concentration of GABA molecule in the solution. The error bars were derived from the repetitive kinetic 
measurement of 26 time points for each concentration of GABA solution. The blue line connects all the 
measurement values. Linear fit of the intensity function curve yield a fit quality factor of 0.9996. 
 
The concentration of electrochemically released GABA from the conducting polymer 
film with and without CNT was quantified by the OPA reagent. Within the 60 μL of PBS for 
drug delivery experiment, 20 μL was sampled and relocated into 96 well plates to be mixed with 
200 μL OPA reagent each. Mixture and reaction time of 100 seconds was selective and 
maintained across all trials due to the time-dependency of the fluorescent intensity. For each type 
of conducting polymer film, 15 trials of accumulative GABA release was executed for first 4 
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repeats of measurements and then the trial number was increased to 30 in order to accumulate 
more GABA molecule and reduce the systemic error during the measurement. The 
PEDOT/CNT/GABA solution denoted as “CNT release” yield the largest quantity of GABA 
molecules released. The release profile of PEDOT/CNT/GABA was close to linear and the 
variation across multiple electrode arrays was very small across all the measured trials. In 
comparison, the release profile of PEDOT/GABA polymer was sporadic, with very high GABA 
release at the beginning of the trials. The error for quantification of GABA concentration was 
accumulated to yield the final standard error value for the accumulative drug release quantity, 
thus the whole PEDOT/GABA release curve yield very large error across all measurements. The 
passive diffusion profile of GABA from PEDOT/CNT/GABA film indicates that a large quantity 
of GABA molecule can be released into the peripheral of the microelectrode without the 
electrical stimulation. This observation was consistent across all 4 electrode arrays measured in 
this group. The PEDOT/GABA film also spontaneously release GABA molecules indicated by 
the green line, with very good repeatability for measurement. Despite the spontaneous diffusion 
of GABA molecules from the conducting polymers after thorough PBS washing of the electrode, 
the electrical stimulation of conducting polymer still significantly increased the total quantity of 
GABA molecules released from the conducting polymers. Overall all types of conducting 
polymer film can release similar quantity of GABA molecule in both spontaneous diffusion trials 
and electrically stimulated trials. The electrical trigger boosted the release amount of GABA 
molecules in each type of conducting polymer. The incorporation of CNT into the conducting 
polymer matrix increased both the spontaneous diffusion of GABA and the electrically 
controlled release of GABA. The most beneficial property of including the CNTs into the 
conducting polymer film is the improvement in the repeatability and total quantity of GABA 
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delivered from the conducting polymer. The semi-linear release profile of GABA can be 
maintained for at least 150 trials when GABA is doped in the PEDOT/CNT/GABA film, while a 
clear decrease of GABA release quantity was observed in all other groups examined, especially 
the electrical release of GABA from PEDOT/GABA film. 
 
 
Figure 3-8 OPA quantification of GABA polymer release. Drug release from PEDOT/CNT/GABA 
polymer yield a more stable and largest accumulative quantity of GABA release over 150 trials (n=3). In 
comparison, the early accumulative diffusion GABA quantity (n=4) was lower than the electrochemically controlled 
release, but the quantity was similar to the active release of GABA from the PEDOT/CNT/GABA polymer. 
However, the quantity of GABA diffusion was lowered significantly during the later phase of release. The quantity 
of GABA release from PEDOT/GABA film (n=3) also demonstrated two different phases. The early drug release 
trials yield a very large quantity of GABA instantly delivered from the film, but significant errors were observed 
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across different electrodes. The later phase of drug release yield a more repeatable and lower quantity of GABA 
from the film. In comparison the diffusion of GABA from the PEDOT/GABA film (n=4) yield lower quantity and 
relatively stable profile across all electrodes. The accumulative quantity of GABA diffused from the PEDOT/GABA 
film was lowest among all groups, but the scale of diffused GABA quantity was similar to the electrochemically 
controlled release. 
 
3.4.3 GABA conducting polymer film support NSC and neuron growth 
3.4.3.1 GABA polymer improve the NSC survival and differentiation  
 The survival of NSC is critical for developing future treatment based on stem cell 
technologies and the differentiation of NSC into neurons is essential to recover the functional 
connectivity of damaged neural networks. On the four types of conducting polymers examined in 
Fig. 3-8A-D,  PEDOT/GABA were the best compared to all other surfaces, with the highest NSC 
counts and highest neuronal differentiation (7.1%) indicated by the neuronal marker beta-III 
tubulin. The PEDOT/CNT film provide better support for the survival of NSC compared to 
PEDOT/PBS coating, with higher percentage of cells differentiating into neurons. While the 
incorporation of GABA into the PEDOT/CNT film enhanced the NSC attachment slightly, the 
ratio of cells differentiating into neurons was not improved over the film without GABA. The 
PEDOT/CNT/GABA film even demonstrated less overall NSC growth and lower neuron 
differentiation compared to the PEDOT/GABA without CNT. The phenomenon is possibly due 
to the change in surface morphology and GABA delivery capability of the conducting polymers. 
In the quantification result of Fig. 3-8E and F, ANOVA was applied to the results and the 
polymer with and without CNT incorporation demonstrated significant difference.  Immobilized 
GABA in the conducting polymer matrix significantly increased the number of survived NSC on 
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the surface. But CNT incorporation in the polymer partially negated the benefit of immobilized 
GABA. In Fig. 3-8F, the neuron differentiation ratio on PEDOT/CNT did not show significance 
over the PEDOT/PBS film, due to the small number of cells available for quantification. 
However, the NSC culture experiment on PEDOT/PBS and PEDOT/CNT substantiated the 
safety and biocompatibility of both PEDOT and CNT material for NSC cultures. 
 
 
Figure 3-9 GABA polymer improve NSC growth and differentiation. (A) NSC culture was performed 
on polymer coated macroelectrode for cell toxicity and biocompatibility evaluation. Hoechst (blue) counter stain of 
cell nuclei, beta-III tubulin (green) staining for early differentiated neurons and GFAP (red) staining for astrocyte 
lineage cells were characterized. PEDOT/PBS polymer is non-toxic to NSC growth, but only limited number of 
NSC can adhere and grow, with a low ratio of beta-III tubulin expressing neurons. Scale bar=100 μm. (B) On 
PEDOT/GABA polymer, NSC can adhere to the surface well and a significant portion of NSC differentiate into 
neurons. (C) PEDOT/CNT support NSC growth and neural differentiation, slightly improved performance was 
observed compare to PEDOT/PBS. (D) NSC can adhere to surface of PEDOT/CNT/GABA and differentiate into 
neurons. The performance is much improved compare to the polymer without GABA. (E) Quantification of cell 
density following NSC culture, the PEDOT/CNT exhibit much better performance to support NSC growth compare 
to the polymer without CNT. The PEDOT/GABA coating demonstrate the best performance among the groups and 
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significantly improve over PEDOT/GABA/CNT coating. (F) Neuron differentiation ratio of NSC culture 
demonstrated similar trend compare to the polymer support for NSC growth, the ratio of beta-III tubulin positive 
cells were observed at highest frequency on PEDOT/GABA polymer, while PEDOT/GABA/CNT polymer shows 
similarly improved performance over non-GABA loaded polymer surface. 
 
3.4.3.2 CNT and GABA facilitate neuron growth and neurite length 
Compare to the NSC culture experiment, the primary neuron culture illustrated a very 
distinctive pattern of facilitation from the different conducting polymers. The best neuron 
survivability was observed on PEDOT/CNT polymer where large number of primary neurons 
maintained after the total duration of cell culture. The neuron count on the PEDOT/CNT was 
higher than both PEDOT/PBS and PEDOT/CNT/GABA condition. The neurite extension on the 
PEDOT/CNT film was also greatly improved over the PEDOT/PBS polymer. PEDOT/GABA 
polymer showed more neuron count compared to the PEDOT/CNT/GABA, but the mean neurite 
length was shorter than that on the PEDOT/CNT/GABA surface. This indicates that the 
PEDOT/GABA polymer created a beneficial environment to maintain a health population of 
neurons possibly by the unique surface morphology as well as leaching out GABA molecules 
into the culture medium, but did not promote neurite growth which is important for network 
formation. Meanwhile, the PEDOT/CNT/GABA film enhanced the extension of processes and 
promoted the formation of the network. Overall the CNT and GABA demonstrated synergistic 
beneficial effect on neurite extension but not the density of neurons.  
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Figure 3-10 Conducting polymer improve neuron growth and neurite extension. (A) beta-III tubulin 
(green) staining for neurons was characterized and utilized as basis of measuring neurite outgrowth. PEDOT/PBS 
polymer supports neuron growth, but the neuron on the polymer surface was sparse, with only limited extension of 
neurites. Limited connection between neurons were observed in the culture. Scale bar=100 μm. (B) On 
PEDOT/GABA polymer, neurons can grow well on the polymer with density of 80 cells/mm2, each neuron extend a 
significant number of neurites with some of them extend far enough to form connection with other neurons. (C) 
PEDOT/CNT demonstrated outstanding performance to support neuron growth and neurite extension, the density of 
neurons reached 120 cells/mm2, significantly improved over the non-CNT modified PEDOT polymer. The 
interconnected neurites were frequently observed. (D) Neurons can adhere to PEDOT/CNT/GABA polymer and 
extend neurite distantly. The direct impact of polymer loaded with GABA is most prominent in neurite extension, 
with some very long neurites connecting distant neurons. (E) Quantification of neuron density on various polymer 
surface, the neuron density was highest on PEDOT/CNT polymer while the PEDOT/GABA polymer outperformed 
the PEDOT/CNT/GABA. (F) Neurite length quantification demonstrated different result comparing to the neuron 
cell density. The incorporation of CNT in the polymer matrix significantly improved the performance of conducting 
polymer for facilitating the elongation of neurites compare to the polymer without CNT. The inclusion of GABA 
molecule perform synergistically with the improvement of CNT, further extending the neurite length. 
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3.4.4 Electrochemically released GABA abolish in vitro neural network activity 
 In order to evaluate the bioactivity of the released GABA, an inhibitory neuro transmitter, 
in vitro hippocampal neuronal network cultured on MED was used. As illustrated by Fig. 3-11A-
C, application of GABA solution released from the PEDOT/CNT/GABA film completely 
abolished the neural network firing, and the effect observed with released GABA solution was 
qualitatively similar to that obtained from direct addition of GABA solution at 10 mM 
concentration. The quantification of this process summarized in Fig. 3-11D validate the firing 
rate observed in the neural network after the washing of GABA solution was comparable to the 
firing rate before the GABA application in both released GABA and 10 mM GABA situation. 
Indicating the GABA solution from drug delivery did not generate long lasting irreversible effect 
on the firing rate of the neural networks. After washing off GABA solution from the cell culture, 
the network activity was recovered but also demonstrated a distinctive synchronized firing state. 
GABA neurons in a network can entrain excitatory neurons to fire synchronously and generate 
oscillatory patterns, so this phenomenon could be due to strong GABA neuron activity after 
recovery from activity reduction.  
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Figure 3-11 MED recording suppressed by electrochemically released GABA. (A) Raster plots of spike 
timings of action potentials recorded on different channels of MED is illustrated in Fig. A. The recorded channels 
demonstrated high firing rate as the baseline for spike number quantification. The network activity was recorded for 
60 seconds, and both synchronous and asynchronous neural activity were observed over the recording period. (B) 
The application of released GABA solution from macroelectrode suppressed all spike generation in the cultured 
neural network. The result substantiate the bioactivity of GABA molecules after being released by the 
electrochemical triggers. (C) After replacing the drug release solution with regular culture medium for washing 
away the GABA molecules, the neural network activity was recovered. The neural network was entrained to 
generate more synchronous firing patterns in the culture medium free of released GABA molecules. (D) The spike 
number suppression effect of released GABA solution demonstrate similar biological effect compare to the GABA 
solution with known concentration. 10 μM GABA solution completely abolished the neural network action potential 
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generation while refreshing the medium can recover the neural network activity to the firing rate similar to before 
the application of GABA.  
 
3.5 DISCUSSION 
3.5.1 Synthesis and characteristics of GABA polymers 
The inclusion of CNT as additive for conducting polymer drug delivery application had 
been proven to increase the quantity of total polymer, increase the mechanical stability and 
improve the electrical property of the film. The Chronoamperometry deposition in Fig. 3-4A 
substantiate the contribution of CNT for increasing the deposition current. Interestingly the 
deposition current was segmented into two fractions switched around 15 seconds. The second 
phase of deposition behaved very similarly to PEDOT/GABA, indicating the dominant 
mechanism for this deposition is the expansion of PEDOT/GABA polymer on the originally 
synthesized film. The first segment was marked by a slightly slower decrease in current, possibly 
due to the increase in surface area by the CNT deposition despite the increase in impedance 
caused by PEDOT/GABA. The overall competing effect was slower decrease in current. In the 
CV measurement for the polymers, the PEDOT/GABA polymer exhibit slightly smaller current 
but increased reduction peak, this may be due to the fact that the CNT films large surface area 
causing more capacitive current and consequently masking the redox peaks of PEDOT. . The 
morphology of PEDOT/CNT/GABA and PEDOT/GABA was examined to elucidate the 
effectiveness of Chronoamperometry synthesis process. The PEDOT/GABA film was very thin 
after polymerization due to a few reasons. First, part of the coating current of PEDOT/GABA 
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could be diverged to the non-faradic charge transfer mechanisms on the electrode surface. 
Second, the adherence of the conducting polymer film with PEDOT/GABA is poor compare to 
PEDOT/CNT/GABA blend. Although the electrochemical polymerization occur around working 
electrode, the synthesized polymers may not deposited on microelectrode surface. Examples of 
this scenario include conductive polymers with significant solubility in aqueous solutions. The 
microscope and SEM examination indicate both PEDOT/CNT/GABA and PEDOT/GABA were 
successfully deposited onto the surface of the Pt/Ir microelectrode. With a much improved 
performance for the PEDOT/CNT/GABA film. The porous structure of PEDOT/CNT/GABA 
resembles the morphology of PEDOT/CNT film but slightly expanded the diameter of individual 
nanofibers in the matrix. The high porosity on the surface of PEDOT/CNT/GABA polymer 
could greatly improve the surface area to volume ratio of the polymer thus increase the ionic 
delivery capability of the film. With the low porosity on the PEDOT/GABA polymer, only a thin 
layer of surface polymer could be utilized for the release of GABA molecules, thus the 
accumulative GABA release quantity may be impaired by the surface morphology. 
 
3.5.2 GABA release quantification 
 The sensitivity of the optimized OPA fluorescent quantification of amine group was 
sufficient to quantify GABA concentration down to 0.2 μM and may even be further extended 
according to Fig. 3-7B. Carefully designed experiment to quantify the GABA delivery from 
various conducting polymer films elucidate very distinct pattern of GABA release in each 
condition. Low surface area to volume ratio was observed on PEDOT/GABA polymer, so the 
GABA molecules ready to be released are most likely aggregated on the outermost surface of the 
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polymer due to the low ionic mobility inside the polymer matrix. This result in a large quantity 
of GABA molecules being released at the very beginning of the experiment. The variation 
between multiple electrode arrays was also very pronounced, possibly due to the quantity of 
GABA molecules that are physically adsorbed with a binding force strong enough to withstand 
the PBS washing. Because the nodular morphology of PEDOT/GABA could form regions with 
very limited ionic mobility and possibly harbor a relatively high concentration of GABA 
molecules in a small volume. In comparison the PEDOT/CNT/GABA almost demonstrated a 
linear profile for the release of GABA molecules. The porous structure of the 
PEDOT/CNT/GABA polymer increased the penetration depth for solution significantly. But 
within the polymer CNT matrix, only limited mobility of ionic species is expected. Furthermore, 
the PEDOT reduction stimulation for triggering drug release was immediately followed by an 
oxidation process to maintain the conductivity and net charge on the electrode surface. Thus 
during the release triggers, the slowly diffused GABA molecules could be re-captured 
immediately, and only move slightly towards the outmost surface of the polymer. This creates a 
very controllable GABA concentration gradient over time, allowing the formation of almost 
linearized release profile of GABA molecules. The porosity of PEDOT/CNT/GABA also 
enabled more GABA molecules to diffuse out spontaneously when the electrode was positioned 
in PBS solution as demonstrated by the blue and green curves in Fig. 3-8. 
3.5.3 GABA containing polymer benefits NSC and neuron growth 
GABA acts as an excitatory transmitter during the early maturation stage of neurons 
instead of inhibitory neurotransmitter[196, 197] and the earliest formation of GABA-releasing 
synapse is before the formation of excitatory glutamatergic contacts in many different neural 
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developmental process. GABA provide important trophic actions and facilitate neuron outgrowth 
during development as well[198, 199]. The presence of GABA molecules from spontaneous 
diffusion of the conducting polymer matrix may improve the survival of NSC and differentiation 
into neurons through this mechanism. With GABA molecules incorporated in PEDOT polymer, 
a very pronounced effect on NSC density and neural differentiation ratio was observed on the 
polymer compared to the film without GABA. Because the lack of nanofiber structures on the 
PEDOT/GABA film, the polymer surface could in full contact with NSC membrane. In 
comparison, the PEDOT/CNT/GABA demonstrated very porous structure and hollow regions on 
the surface of the polymer. The morphology is beneficial for diffusion and release of GABA 
molecules in PBS solution, but the effective surface in direct contact with NSC membrane is 
significance limited by this nanofiber texture. The NSC growth and differentiation may benefit 
most from the direct contact with conducting polymer due to the gradual diffusion of GABA 
molecules through from the matrix, so the culture of NSC on PEDOT/GABA/CNT polymer only 
demonstrated limited beneficial effect.  
The neurons however, demonstrated a different trend on various conducting polymer 
surfaces. The most beneficial surface for primary neuron culture was observed on PEDOT/CNT 
and PEDOT/CNT/GABA, with the highest density of neurons observed on PEDOT/CNT and the 
longest average neurite on PEDOT/CNT/GABA. As mentioned previously, GABA molecules 
could significantly accelerate the maturation of neurons due to the lack of glutamatergic 
transmission in early developmental stages, so the extensive neurite outgrowth could be an 
indication of more mature neurons ready to form interconnected networks. The PEDOT/CNT 
polymer exhibit the best conductivity among the various types of conducting polymers, the 
phenomenon could be relevant to the beneficial carbon nanotube substrate for increase the 
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neuron electrical signaling[200]. Furthermore, the nanofiber structure of the PEDOT/CNT 
polymer could possibly interact with surface structural proteins of cells and stimulate the 
adhesion and outgrowth of neurite due to the similarity of size between the nanowires and 
neurofilament proteins with specific molecular weights[201]. 
3.5.4 Electrochemically released GABA maintain bioactivity 
The MED technique is developed as a high throughput and highly repeatable platform for 
in vitro assessment of experimental treatment to neural networks or other tissue with 
bioelectrical activities [202, 203]. The cultured neural network is suitable for evaluating the 
bioactivity of released GABA molecules from the polymer matrix. Due to the lack of complex 
input to the cultured neural network, the in vitro culture of neurons normally demonstrate a high 
firing rate at quiescent conditions[204]. The culture thus provide an exceptional experimental 
baseline condition for testing inhibitory effect of GABA solution. With the addition of GABA 
released from the PEDOT/CNT/GABA film, the network firing recorded on MED was 
completely abolished, indicating the GABA molecules remain bioactive after the electrochemical 
polymerization and electrically controlled release from the film. 
3.5.5 Future works for GABA release. 
The PEDOT/CNT/GABA film exhibit beneficial properties for many various types of 
applications to neural tissue in this study. The utilization of the conducting polymer film and 
drug delivery technique could benefit the neuroscience research and possibly treatment of neural 
disorders[156]. To further evaluate the system, the in vivo application of the drug delivery 
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experiment should be performed to verify the effectiveness of the technique. More detailed 
quantification of GABA release from various microelectrode surface could significant improve 
our understanding of the dynamical process of zwitterionic molecules being incorporated and 
released from conducting polymer matrix. The use of other nanomaterials such as Graphene 
Oxide (GO) as co-dopant could potentially provide other beneficial properties due to the high 
surface area ratio and the unique electrical and physical properties[205]. This neurotransmitter 
releasing conducting polymer films can be a promising candidate as for neural interface and 
neural regeneration research.  
 
3.6 CONCLUSIONS 
GABA molecules can be successfully incorporated during the synthesis of PEDOT 
polymer and the inclusion of CNT can facilitate the polymerization process as well as providing 
a more linear release profile. With carefully designed OPA fluorescent reaction, GABA 
molecules diffused and released from the conducting polymer film was precisely quantified. The 
result indicates GABA can be released up to 90 μg/cm2 by 1.5 V cosine waveform. The released 
GABA solution retained bioactivity to suppress neuronal firing in an in vitro cultured neural 
network. NSC and neuron cultured on various GABA, CNT and PEDOT film demonstrated the 
facilitation effect of GABA for NSC survival and differentiation. The CNT facilitate NSC 
growth without incorporating GABA molecule but impaired the performance of GABA for 
enhancing NSC growth. However, CNT contribute significantly to the growth of neurons and 
extension of neurites while GABA demonstrated synergistic facilitation effect to a limited 
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extend. Overall the zwitterionic molecule GABA was successfully delivered with our 
electrochemically controlled drug release system based on PEDOT and CNT and the polymer 
surface demonstrated beneficial effect for NSC and neuron cultures. 
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4.0  MODULATION OF IN VIVO BARREL CORTEX NEURAL NETWORK 
ACTIVITIES WITH ELECTROCHEMICALLY CONTROLLED RELEASE OF 6,7-
DINITROQUINOXALINE-2,3-DIONE (DNQX) 
4.1 ABSTRACT 
Conducting polymers can be electrochemically deposited on electrodes with negatively charged 
dopant molecules incorporated. When electrically stimulated, the dopant molecules can be 
released. This property of conducting polymer can be utilized to deliver various biological 
molecules into the body in controlled manner. Previously we have shown delivery of CNQX (6-
cyano-7-nitroquinoxaline-2,3-dione), an AMPA (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-
yl)propanoic acid) receptor antagonist in hippocampal neuron culture diminished 
neurotransmission and reduced neuronal spiking. In this work the drug delivery technology is 
further developed and evaluated with DNQX (6,7-dinitroquinoxaline-2,3-dione) release in rat 
somatosensory (S1) barrel cortex. Barrel cortex neural activity reliably represents sensory 
stimulation from facial whiskers in a topographical manner. The repetitively quantifiable neural 
network in barrel cortex thus provides an excellent test bed for evaluating our local drug release 
system in vivo. Multi-whisker air puff stimulation is utilized to evoke repeatable neural firing in 
layer IV of barrel cortex. The recorded neural activity can be immediately suppressed by the 
delivery of DNQX for one to six seconds within the 300 μm, demonstrating the high spatial and 
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temporal selectivity of this novel drug delivery system. Furthermore, weaker neural activities 
after whisker stimulation can be nearly abolished by the released DNQX whilst stronger evoked 
activities were less affected, due to the sigmoidal activation function of neurons. This system 
demonstrates successful high precision modulation of neural network activity. With the ease of 
being incorporated in existing extracellular neural electrode devices without increasing the 
volume or complexity, this technology may advance basic neuroscience research as well as 
therapies for neurological disorders and injuries.  
4.2 INTRODUCTION 
Neural network activity on various scales underlies numerous neural functions such as 
cognition, learning, and memory [159, 160]. Many functional neural network abnormality 
accounts for neuronal diseases [206, 207]. To understand the in vivo neural network activities, 
Multielectrode Arrays (MEAs) with the capability of recording from ensembles of neurons or 
stimulate a small population of local neural networks have been developed to understand neural 
networks and correct abnormal activities [208, 209].  Neural modulation techniques are often 
required to dissect the function of neural networks in complicated neural processes. Such 
techniques include neural stimulation[135, 137], systemic injection[183], localized cannula 
injection[57], microdialysis[210, 211], iontophoresis[46, 212-214], and optogenetics[72, 74].  
However, due to the already complicated in vivo MEA fabrication process and the required 
feature to integrate components into extremely small space[9, 10, 113, 215], the ideal neural 
interface systems with pharmaceutical modulation of recorded neural networks has yet to be 
realized. Because drawbacks were observed with each class of localized neural modulation 
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techniques, including the lack of spatial and temporal precision of the modulation effect. In some 
cases, the ongoing neural modulation treatment abolish the recording of MEAs from targeted 
neural tissue completely. The conventional techniques for cannula injection of neuroactive 
molecules cause neural tissue damage from the bulky size of device as well as the volume 
change during injection. The microfluidic device with pharmacological intervention capability 
requires additional complex steps of manufacturing thus raise the failure rate of device [216-
218]. Furthermore, the addition of fluidic channels suffer from undesirable chemical leaking and 
clogging of channels when utilized for chronic applications. Optogenetics technique demonstrate 
outstanding performance for the modulation of specific genetically modified neurons[219-221], 
but the technique is restricted by the availability of genetic modified channels in target species, 
the positioning of fiber optics[75], the involvement of light source, as well as photoelectric 
artifact[222].  
Conducting polymer coatings create an attractive means for localized pharmaceutical 
modulation of neural network activity directly from the neural microelectrodes. These polymers 
can be electropolymerized with oxidative current and deposited onto any electrodes from 
aqueous solution of monomers and electrolytes, resulting in positive charges on the backbone. 
During the polymerization, negatively charged species in the solution may be incorporated into 
the polymer coating as dopants. Negative electrical currents reduce the polymer in to a neutral 
form, release the dopants and electrostatically drive the drug molecules out. Based on this 
mechanism, the electrically controllable delivery of various reagent have been demonstrated, 
include anionic salicylate, adenosine triphosphate (ATP), 2-ethylhexylphosphate (EHP), and 
naproxen and dexamethasone [168-171]. 
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Previously, electrically triggered release of CNQX (6-cyano-7-nitroquinoxaline-2,3-
dione), an AMPA (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) receptor 
antagonist  based on this mechanism has been demonstrated to effectively reduce spike firing 
rate in hippocampal neural cultures in a manner [154]. Here we report the further development of 
this technology for in vivo use. The fast glutamate transmission mediated by AMPA receptor is a 
suitable target for pharmaceutical modulation of neural network activities due to the strong 
involvement of AMPA current in generating action potentials in vivo[223, 224]. Instead of 
CNQX, another AMPA receptor antagonist DNQX has been selected to demonstrate the 
effectiveness of this conducting polymer based technique in vivo [225-227].  
Both molecules CNQX and DNQX are poor dopants, i.e. they significantly impair the 
electrical conductivity of the synthesized polymer film, thus only allow the formation of a very 
thin layer of conducting polymers with little drug loading capability. A bi-layer approach of 
incorporating PEDOT and functionalized carbon nanotubes (CNTs) has been developed to 
ameliorate this difficulty.  
The incorporation of CNT into our drug delivery systems utilizes multiple unique 
features of this material. First, CNT has demonstrated excellent adherence and stability on 
electrode surface. Secondly incorporating CNTs can improve the conductivity of the conducing 
polymer matrix [94, 95, 110], which is critical when poor dopants such as CNQX and DNQX are 
used. The first layer of the coating consists of PEDOT/CNT, which provides a highly conductive 
and adherent substrate with high surface area topography that benefit the growth of the second 
layer[128],  consisting of PPy/CNT/DNQX.  PPy was selected due to increased drug 
incorporation quantity over other polymers and the low amplitude of reduction potential to 
switch the redox state of the polymer backbone. Incorporation of CNT in the PPy matrix allows 
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the formation of a more stable conducting polymer matrix to endure the repetitive application of 
drug release triggers, meanwhile the internal cavity of CNT serves as an excellent reservoir to 
increase the total amount of drug molecules can be released[125].   
 Rat somatosensory (SI) barrel cortex serves as an outstanding testbed to evaluate our 
drug delivery system due to the reliable action potential firing mechanism which is 
topographically evoked by stimulating specific facial whiskers[152, 228-230]. The barrel cortex 
input neural network in layer IV is selected as the target neural network for local modulation due 
to the high transient firing rate, high reliability, low spontaneous firing and low latency of the 
neurons[231]. In this work, the microelectrode array coated with bilayer PEDOT/CNT and 
PPy/CNT/DNQX conducting polymer was implanted into rat barrel cortex acutely. Air puff 
multi whisker stimulator was utilized to elicit strong and repeatable neuronal firing 
patterns[157]. The effect of electrically triggered DNQX release on sensory evoked neural 
response was characterized. 
4.3 MATERIALS AND METHODS 
4.3.1 Materials and Electrodes 
4.3.1.1 Materials 
DNQX disodium salt was acquired from Abcam (MA) or Alomone Labs (Israel), Multi-
walled carbon nanotubes (CNT) was purchased from Nanoamor (TX) and was chemically 
functionalized with –COOH with previously reported method [125]. 
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16 channel microelectrode arrays for in vivo neural recording and drug delivery was 
obtained from Neuronexus (MI). The GSA of electrode sites on the probe was 704 μm2. The 
electrodes are arranged on 4 shanks with 4 electrodes on each shank. The site spacing on each 
shank is 100 μm and the shanks are 125 μm apart from each other. The sites expand a depth of 
300 μm, allowing all recordings to be performed within layer IV of barrel cortex. 
CNT were functionalized with carboxyl groups with acid treatment, the procedure is 
briefly described as follows: first CNTs were sonicated in acid solution (1:3 HNO3 and H2SO4) 
for 2 hours rendering the inner and outer walls of CNTs hydrophilic. This treatment also opens 
the CNT ends and removes the heavy metal. Ultracentrifuge (Sorvall RC 6 plus, Thermo 
Scientific, PA) at 12k-19k rpm was employed to remove the residual acid from the CNT and DI 
H2O was added to serially dilute the residual acid in the CNT. After the pH of CNT solution is 
neutral, the CNT were first completely dried at 50 oC.  
4.3.2 Electrochemical synthesis and characterization 
PEDOT/CNT films were electrochemically deposited onto microelectrodes in a solution 
of 0.015 M 3, 4-ethylenedioxythiophene (EDOT) monomer, 1.5 mg/mL CNT dissolved in DI 
H2O. The deposition solution was sonicated with a probe sonicator for 10 minutes to create 
homogenized suspension solution. Chronoamperometry deposition of PEDOT was controlled by 
a FAS2 Femtostat (Gamry, PA) at 0.95 V for 20 seconds in a three electrode setup 
electrochemical chamber. A platinum sheet was utilized as counter electrode and a Ag/AgCl wire 
as reference electrode. The microelectrode array was carefully lowered into the deposition 
solution with a micromanipulator (WPI, FL). Custom built electrode holders and connector wires 
were used to switch the coating channel in sequence without moving the microelectrode array in 
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solution at all. The concentration of EDOT monomer was slightly increased than the solubility 
due to the extremely large surface area of CNT might absorb large amount of EDOT monomers 
and decrease the monomer content in the deposition solution. After synthesize of PEDOT/CNT 
the array was carefully lift out from deposition solution and immediately rinsed with DI H2O to 
remove excess deposition solution and loosely attached particles. Then 1 mg/mL CNT is 
dissolved in 5 mg/mL DNQX high concentration solution. The process that H2O enters the 
internal cavity of CNT requires great effort and is only ideal when the dry CNT is first 
dissociated in H2O. So the high concentration DNQX solution can be easily carried into the inner 
cavity of CNT to serve as drug release reservoir. The solution was sonicated for 5 minutes until 
0.45 M pyrrole monomer was added and additional 5 minutes of sonication homogenize the 
pyrrole, CNT and DNQX together. The same electrochemical setup was utilized to deposit the 
PPy/CNT/DNQX film on PEDOT/CNT pre-coated electrodes. The Chronoamperometry 
deposition was maintained at 0.75 V for 15 seconds. Electrical stimulation electrodes serve as 
control experiments with PPy/CNT on PEDOT/CNT coatings were prepared with same 
Chronoamperometry parameters while only Py monomer and CNT were sonicated in DI H2O for 
deposition.  Electrochemical Impedance Spectra (EIS) scan was performed on uncoated, 
PEDOT/CNT coated and double layer PPy/CNT/DNQX coated electrode sites. The data was 
imported into MATLAB (Mathworks) and analyzed for direct comparison. 
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Figure 4-1 Illustration of drug release microelectrode array and double-layer coating. The 
microelectrode array obtained from Neuronexus has four shanks, with four microelectrodes on each shank. The site 
spacing on same shank is 100 μm and the shank spacing is 125 μm. Multiple drug coated microelectrodes are 
combined to maximize the effect of released DNQX into the barrel cortex. The drug releasing microelectrodes were 
separated by recording microelectrodes in order to obtain neural modulation on different concentration scales. On 
each microelectrode, the electrode material is composed of Iridium (Ir). Other metals utilized for fabrication of these 
microelectrode arrays include Gold (Au), Platinum (Pt) and Pt/Ir alloys. Selection of microelectrode materials is 
determined by the requirement for mechanical properties and conductivity as well as surface adhesion properties 
such as formation of Self-assembled monolayer (SAM) materials. On the electrode materials a layer of 
PEDOT/CNT was electrochemically deposited to expand the surface area of the electrode and decrease the surface 
impedance. Then the PPy/CNT/DNQX layer is synthesized to precisely delivery DNQX molecules to the neural 
networks adjacent to the implant and modulate the activity during recording sessions. The electrode traces and were 
insulated while the microelectrode sites were exposed, the conducting polymer matrix slightly grow over the region 
of microelectrode and extend onto the surface of insulations, rendering the effective electrode surface areas bigger 
than the original microelectrode. 
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4.3.3 In vivo DNQX release modulate barrel cortex activity 
4.3.3.1 Air puff stimulator for evoking barrel cortex activity 
A portable air compressor with compressed air tank was used to deliver 15 psi air puff 
stimulation to the rat facial whiskers. A custom built multi-channel manifold with solenoid valve 
receiving multi-channel TTL signal controlled the pattern of air puff stimulations. The digital I/O 
port on RX5 (TDT) recording processor was utilized as control signal for the on and off of air 
puff whisker stimulator. An externally powered custom built electrical circuit was utilized to 
ascertain the generation of 5 V TTL signals to precisely control the solenoid valve. A 
piezoelectric sensor directly held at the puffer nozzle generated electrical signal in order to 
measure the delay in the air puff sensory stimulation system. The electrical signal from 
piezoelectric sensor and the RX5 I/O port were both recorded on oscilloscope for direct 
comparison. The air puff system created 20 ms delay in the process of delivering compressed air 
to the rat facial whiskers. 
4.3.3.2 Barrel cortex surgery for simultaneous recording and stimulation 
All animal work was performed under the guidelines of the University of Pittsburgh 
Institutional Animal Care and Use Committee (IACUC). Sprague-Dawley (SD) rats were 
anesthetized under 3% isoflurane and head-fixed in a SR-6R stereotaxic frame (Narishige, NY). 
Two skull screws were carefully positioned above the right motor cortex and left visual cortex of 
the rat illustrated in Fig. 4-2A. The screws barely touch the surface of the brain to provide 
conductivity but without being affected by the slow oscillatory signals generated by the brain. A 
3 mm by 3 mm semi-transparent window above the somatosensory barrel cortex (SI) of the right 
cortical hemisphere was created by thinning down the skull using a motorized drill. Saline was 
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repetitively applied to the skull surface during the drilling process to remove excessive heat 
generated in the process. The motorized drill speed was controlled by a foot unit to apply high 
speed drill at the beginning of the surgery but very carefully controlled low speed drill when 
approaching the brain surface. The center of barrel cortex coordination were of 2.5 mm posterior 
to Bregma and 5.5 mm lateral to the midline. After carefully examine the blood vessel patterns 
underneath the semi-transparent skull window, a 1 mm by 1 mm craniotomy was opened on the 
brain surface with forceps and surgical blade. The dura mater was recessed with a bent 30 Gauge 
needle and a spring loaded micro scissors. The neural probe was inserted into the cortex using a 
micromanipulator at a slow speed to 900 μm beneath the cortical surface where the layer IV of 
barrel cortex is located, as demonstrated in Fig. 4-2B. The recording performance of the 
implanted microelectrode array was carefully optimized once the principle whisker was 
discovered. A custom built electrode adapter was utilized to assign neural stimulation and 
recording functions to individual sites on microelectrode array. The adapter was specifically 
designed to completely segregate the neural recording and electrical stimulation circuit in order 
to ensure the safety of neural recording during simultaneous stimulation trials and reduce the 
impact of artefact on the neural recording quality. Multi-channel neural stimulation signal to 
trigger the release of DNQX embedded in the conducting polymer matrix was generated by an 
MS16 stimulator (TDT) controlled by an RX7 (TDT) stimulation based recording unit. The 
neural signal from microelectrode array was amplified using a 16 channel Medusa preamplifier 
and recorded using an RX5 processor at 25 kHz sampling rate (TDT, FL). Neural signal was 
subsequently imported into MATLAB with custom scripts for analysis. The synchronization of 
neural recording, drug release trigger and whisker air puff was controlled by RX 5 and RX 7 
unit. Contralateral air puff to facial whisker was delivered by the whisker stimulator. The air puff 
 98 
stimulator nozzle was made of a flat-end needle. The nozzle was carefully positioned around 1 
cm above the top row of whiskers with a helping hand and repetitive air puff stimulations 
controlled by recording processor was delivered onto facial whiskers to confirm the principle 
whisker of the barrel that the neural electrode array was implanted into. The air puff stimulator 
was held about 1.5 cm above the principle whisker and 15 psi air puff reliably evoked strong 
neural activity in the layer IV of barrel cortex. Each air puff stimulation to the whisker lasts 100 
ms in duration and was delivered at 4 Hz to evoke strong neural response. Once the principle 
whisker for the implant is optimized, the electrode depth was slowly adjusted with simultaneous 
whisker stimulations and audio amplitude representation of whisker evoked response. The probe 
is located at the depth in layer IV to evoke the strongest sensory response from the principle 
whisker. 
 
 
Figure 4-2 Neural surgery and experiment paradigm for whisker stimulation. (A) The schematics 
demonstrating the experiment setup. The craniotomy was opened in rat barrel cortex centered at -2.5 mm post 
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Bregma and 5.5 mm lateral to midline. Neural recording and drug delivery array was inserted slowly with a 
micromanipulator until layer IV of barrel cortex. Two ground screws were placed in the skull, one recording ground 
screw in right motor cortex and one stimulation counter screw in left visual cortex. The air puff stimulator was held 
above the principle whisker of the implanted barrel on the contralateral side of the face. (B) Illustration of cortical 
layers for neural recording. The layer IV is one of the major input layers of the barrel cortex with clear topographical 
segregation of neural networks representing different whiskers. Another low latency input to the cortical layers was 
observed in layer VI of barrel cortex. The layer IV of barrel cortex is typically 600-1000 μm from the surface of the 
brain. Optimal neural recording was usually achieved around 900 μm. In certain cased the probe might be inserted 
into the Septa region between barrel networks in layer IV, the evoked response in Septa region is weak so the probe 
is sometimes repositioned to achieve the highest firing rate from the principle whisker.  
 
4.3.4 Experiment paradigms for evaluating the DNQX effect in barrel cortex 
A cosine waveform with amplitude of -3 μA and duration of 100 ms was delivered to 
each microelectrode to trigger the release of DNQX from the microelectrode, as illustrated in 
Fig. 4-3A. The cosine waveform can deliver sufficient charge to the conducting polymer surface 
with a slow rate of increase in the current. Fast change in neural stimulation current can induce 
massive capacitive current on the membrane of neurons thus change the firing property of 
neurons. So the slow change of cosine waveform will cause faradaic reaction on polymer 
electrode and release drug without affecting the neural firing property on its own. The drug 
release current is followed by a reverse phase current with 1.5 μA amplitude and 200 ms duration 
in order to balance the change. The charge balance phase serves two functionalities: reduce the 
net charge delivered to local tissue in order to maintain the safety of the neurons adjacent to the 
probe, and partially reverse the reduction of PPy polymer so the conjugated polymer maintain 
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sufficient conductivity for the following drug release triggers. In Fig. 4-3B, the air puff 
stimulation to the whiskers is delivered in burst of three air puffs, at 4 Hz frequency. The 
duration of air puff is 100 ms and the interval between air puffs is 150 ms in order to control the 
air puff at 4 Hz. The spikes generated in this sensory stimulation pattern amounts to higher firing 
rate than single air puff stimulation. The intensity of each burst of air puff is sufficient to 
quantify the effectiveness of released DNQX molecules. In Fig. 4-3C the experiment time chart 
is briefly demonstrated, the beginning of the first air puff burst is designated as 0 second, five 
consecutive bursts of air puffs were first delivered before the drug release trigger to establish a 
stable baseline of neural response. The drug release trigger was applied at 29 seconds, one 
second before the 6th burst of air puff. Then additional ten air puff bursts were delivered after the 
drug release trigger in order to quantitatively assess the effectiveness and duration of the 
delivered DNQX molecule. Each drug release session is 90 seconds in total duration. At least 
one additional minute was allowed before the next drug release trial begins in order to allow the 
wash away of previously released DNQX molecules and the recovery of AMPA receptors in the 
barrel cortex.  
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Figure 4-3 Experiment design to evaluate DNQX release in barrel cortex. (A) The cosine waveform to 
trigger drug release from microelectrode last 100 ms and is followed by 200 ms half amplitude charge balance 
phase. The release is represented by the green trigger in (C). (B) The air puff stimulation delivered to the principle 
whisker is 100 ms in duration and 4 Hz in frequency. The total duration of the air puff is 300 ms, with 450 ms 
following the air puff for quantification of spike numbers in the interval of sensory stimulations. (C) Five bursts of 
sensory stimulations were delivered to the principle whisker for establishing the baseline spike count before the drug 
release trigger was applied to the release electrodes. Each burst of whisker stimulation is delivered at 0.1667 Hz to 
allow sufficient time for receptors in the barrel cortex to recover from adaptation effect. The drug release trigger was 
applied one second before the 6th whisker stimulation burst. Ten additional whisker stimulation bursts were 
delivered to the principle whisker to evoke neural activities in order to observe the effective duration of the released 
DNQX molecules. 
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4.3.5 Neural data analysis and quantitative assessment of drug release 
4.3.5.1 Neural data preprocessing 
The raw data stream recorded at 25 kHz was imported into MATLAB and processed with 
custom scripts. The spike data stream was generated by band pass filter the raw data stream 
between 300 Hz and 3000 Hz, because the typical waveform frequency of extracellular action 
potentials is about 1000 Hz. 1 Hz to 300 Hz band pass filtered waveform represent the LFP 
(local field potential) of the data stream. After the filtering process, common average reference 
(CAR) technique was applied to all data streams on recordable neural electrodes, in order to 
calculate the common fluctuation in the data waveform to remove simultaneous artefacts and 
waveform deviation caused by the reference electrode. CAR component is then removed from 
each individual recorded waveform. The standard deviation (SD) of the spike data stream was 
calculated and 3.5 times SD was utilized to threshold the waveforms with amplitudes higher than 
the threshold. All threshold crossing waveforms with 0.4 ms before and 0.8 ms after the 
threshold crossing time point was removed from the spike data stream. Next the SD of data 
stream without threshold crossing waveforms was calculated and 3 times this SD is utilized as 
the final threshold for detecting threshold crossing extracellular action potential waveforms. The 
spiking time points of these multi-unit recording waveforms were utilized to calculate the firing 
rate and the drug release effect of the system. 
4.3.5.2 Quantification of drug release on sensory input 
During each burst of air puff stimulation, high firing rate was observed during the 100 ms 
period when air puff was turned on, and relatively low firing rate was observed during the 150 
interval period between air puffs. After the third air puff, additional 150 ms was utilized to 
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calculate the firing rate of the neurons in this non-sensory response period. Because the air puff 
stimulator may generate oscillatory mechanical movement on the principle whiskers, and this 
effect of air puff could last after the solenoid is already switched off. Thus the non-sensory 
response period also demonstrate higher firing rate compare to the spontaneous baseline duration 
of the recording sessions. Each air puff stimulation in the three burst delivered at 4 Hz is 
characterized by one sensory response period and one non-sensory response period. The three 
consecutive sensory response period elicit weaker response towards the end due to the adaptation 
of the neural response. But the sensory response firing rate was still much higher than the non-
sensory response firing rate. The sensory and non-sensory response of each period was 
calculated for the three air puff stimulations and the drug effect on each of these period was 
compared to the regular firing rate during the baseline recording to yield the drug release 
suppression ratio of these firing rates.  
4.3.5.3 Effective drug delivery trials and distance 
On 16 channel multielectrode array for recording and stimulation, four channels were 
utilized to deliver DNQX to the local neural network. During electrically evoked control 
experiments, another four microelectrodes with only PEDOT/CNT and PPy/CNT double layer 
polymer coating without DNQX molecules were utilized as electrical control stimulation to 
evaluate the effect of drug release trigger waveforms on the recorded neural networks. During 
control experiment another four recording channels were utilized for drug release triggers, so a 
maximum recording channel number of 12 is achieved during each drug release experiment. The 
sensory evoked firing rate response observed on the 12 recording channels were averaged 
together in order to evaluate the total impact of DNQX release on the local neural network 
during one single drug release trial. During different drug release experiments, the corresponding 
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release trial of DNQX from the first release after fresh polymer coating towards the end of the 
experiment was considered equivalent DNQX release trials and multiple recording channels 
were analyzed together to obtain the general trend of neural response suppression caused by 
DNQX release.  
Furthermore, analysis was conducted to evaluate the spatial resolution of the released drug 
molecules. As demonstrated in Fig. 4-1, each of the four DNQX release sites was considered to 
generate a semi-sphere diffusion concentration gradient of DNQX following the drug release 
trigger. Due to the spatially restricted diffusion of molecules inside the brain, the semi-sphere 
estimation was a preliminary estimation of the drug release concentration pattern, but the effect 
of the drug release concentration variation during each experiment can be overcome by the high 
number of experiments to repeat the DNQX release because the spatial restraint on DNQX 
diffusion is considered randomly anisotropic. The summation result of the four semi-sphere 
DNQX concentration patterns following each drug delivery trigger cause the highest 
concentration of DNQX to occur on the center of the four release sites. In Fig. 4-1 the highest 
concentration of DNQX occur on electrode site 10, and the quantity of DNQX decrease as the 
recording electrode is further from site 10 as the DNQX release center. The distance effect of 
DNQX release is summarized by quantification of firing rate reduction correlating with the 
increase of distance from the highest concentration of DNQX release. A second order 
polynomial function was fitted to the distance-suppression effect plot, thus the distance at which 
the drug effect would vanish could be extrapolated from the fitting polynomial function despite 
the limited recording sites on the recording probe. 
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4.4 RESULTS 
4.4.1 Synthesis and characterization of double layer DNQX release polymer 
4.4.1.1 Electrochemical synthesis and property of double layer PPy/CNT/DNQX 
Electrochemical synthesis of PPy/CNT/DNQX polymer was hindered by the 
incorporation of DNQX a in the polymer film. Typically PPy polymer with good dopants forms 
films with good conductivity and as the film grows thicker and rougher, the impedance drops, 
resulting in continuous increase in the deposition current. However the incorporation of DNQX 
molecule greatly increase the surface impedance of electrode and decrease the coating current 
(Fig. 4-4A), suggesting a low conductivity of the resulting film. The synthesis of first layer 
PEDOT/CNT polymer partially solve this problem by decreasing the initial impedance and 
increase the initial effective area for PPy/CNT/DNQX coating. The PPy/CNT/DNQX 
Chronoamperometry deposition current on top of the PEDOT/CNT film is illustrated as the blue 
curve in Fig 4-4A, while the PPy/CNT/DNQX Chronoamperometry current of PPy/CNT/DNQX 
on unmodified microelectrode was represented by the red curve in Fig 4-4A. The bilayer 
PPy/CNT/DNQX deposition current demonstrated much higher initial current and accumulated 
charge. The blue curve demonstrated two decreasing rate feature during different time period due 
to the fact that PPy/CNT/DNQX polymer can simultaneously increase coating current by 
increasing electrode surface area and decrease coating current due to poor polymer conductivity. 
The first period before 5 seconds demonstrated a faster decreasing rate of deposition current, due 
to the high rate of DNQX polymer synthesis completely dominant over increase of polymer 
surface area. However after 5 seconds, the resistivity increase by DNQX polymer already 
decrease the deposition current significantly, thus the effect of increased polymer surface area 
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roughly balance out the further decrease of polymer conductivity. This phase benefit from the 
high initial surface area of the PEDOT/CNT polymer and contribute to the major portion of 
increase in total deposition charge. In Fig. 4-4B, the EIS measurement of different electrode 
surface was compared to each other. The most emphasized impedance value for extracellular 
action potential is 1000 Hz because the characteristic frequency of recorded action potential 
waveforms correspond to this frequency. For the conductivity of polymer film and the capability 
to deposit polymers onto the electrode surface, the low frequency impedance near DC current is 
the major determine factor. For uncoated microelectrodes, the impedance value at 1000 Hz is the 
highest among the measured electrode surface. The impedance of typical electrode site for neural 
recording at 1000 Hz is between 500 kΩ and 1 MΩ. The deposition of PEDOT/CNT greatly 
decreased the impedance of the microelectrode to the green curve, with 1000 Hz impedance 
around 20 kΩ. After the synthesis of second layer PPy/CNT/DNQX polymer the electrode 
impedance ends around 200 kΩ at 1000 Hz. Due to the importance of 1000 Hz impedance value 
for extracellular action potential recording performance of microelectrodes, the double layer 
DNQX polymer can improve the recording quality of the coated microelectrode. The recording 
of double layer PPy/CNT/DNQX coated microelectrodes were utilized during electrical control 
trials where double layer PPy/CNT polymer coated electrodes were utilized for evaluation of 
electrical stimulation effect. 
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Figure 4-4 The electrochemical synthesis and EIS measurement of double layer DNQX polymer. (A) 
Electrodeposition current comparison between single layer PPy/CNT/DNQX polymer (example 
Chronoamperometry curve, n=3 electrodes demonstrated same curve) and double layer PPy/CNT/DNQX polymer 
as second layer polymer on PEDOT/CNT (n=3). The single layer coating current start at high amplitude about 1.5 
μA but decrease rapidly over the duration of polymerization. The total charge for deposition is limited and the final 
impedance of the conducting polymer was high so the voltage for drug delivery trigger was high, causing severe 
redox side effects to the electrode and local tissue. With double layer PPy/CNT/DNQX on top of PEDOT/CNT 
polymer, the deposition current is greatly increased, the deposition charge increment benefit the total polymer with 
DNQX molecules and the higher ending current benefit the lower drug release trigger voltage caused by the control 
current. (B) EIS measurement of electrode sites with different modifications, the black curve demonstrate the initial 
microelectrode impedance value. The impedance was highest among the measured groups in the high frequency 
range but the increment rate of impedance towards low frequency range was moderate. The PEDOT/CNT film (n=3) 
greatly reduced the impedance in all frequency range compare to the uncoated microelectrodes (n=3). The double 
layer PPy/CNT/DNQX polymer (n=3) increased the impedance of the electrode in almost all frequency range, due to 
the low conductivity of the polymer with DNQX dopant. The increase in impedance was prominent at both 1000 Hz 
and the lowest frequency 10 Hz, corresponding to the performance of extracellular action potential recording and 
further electrochemical deposition, respectively.   
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The microscopic examination of PEDOT/CNT and PPy/CNT/DNQX polymer was 
performed under optical microscope. The PEDOT/CNT conducting polymer formed a uniform 
layer of polymer that appears dark in color due to the light absorption by CNT. The polymer 
coating increase the microelectrode surface area slightly, but does not significantly impact the 
regional specificity for neural recording or stimulation of the coated electrodes. The double layer 
PPy/CNT/DNQX coating does not change the appearance of the conducting polymer. Because 
the surface morphology of PEDOT/CNT polymer examined under SEM demonstrate nano 
features and large surface area to volume ratio in chapter 1, the PPy/CNT/DNQX coating slightly 
thickens the PEDOT/CNT polymer without horizontally expand the surface are of polymer 
coated microelectrodes. After the in vivo drug release experiment, microelectrode arrays were 
removed from the cortex and dipped in warm Trypsin solution for 10 minutes to remove the 
tissue on the electrode surface. The electrode array can be coated again with PPy/CNT/DNQX 
polymer and reused for DNQX delivery purposes. The morphology of microelectrodes showed 
no observable change under the microscope before and after in vivo use, demonstrating that the 
mechanical perturbation during probe insertion into the brain and the electrical stimulation 
during the drug delivery did not cause the double layer PPy/CNT/DNQX coating to delaminate 
under microscope.  
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Figure 4-5 Microscopy examination of conducting polymer coated microelectrodes.  (A) 
Representative images of double layer PPy/CNT/DNQX coated microelectrodes sites among the uncoated Iridium 
microelectrodes. The deposition of first layer PEDOT/CNT polymer significantly change the surface appearance of 
the electrode but only slightly increase the electrode surface area. The second layer PPy/CNT/DNQX coating does 
not increase the area of microelectrode at all. The deposition of polymer on microelectrode is uniform and covers the 
microelectrode completely. (B) After acute neural surgery for DNQX release, the microelectrode array was 
explanted from the brain and treated with trypsin to remove the tissue debris on the surface of microelectrodes for 
reuse. Representative images of the conducting polymer coating morphology indicate the polymer did not change at 
all during the drug release experiment.  
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4.4.2 In vivo DNQX release in barrel cortex 
4.4.2.1 Neural recording in barrel cortex with sensory evoked activity 
The raw neural signal filtered between 300 Hz and 3000 Hz were utilized to analyze the 
extracellular action potentials recorded in the barrel cortex as demonstrated in Fig. 4-6. The air 
puff stimulation evoked strong neural network activity during the period of stimulation and the 
interval between puffs. The firing pattern during the interval of air puffs could be result of 
repetitive firing of excitatory neural networks or the vibration of facial whiskers following the 
stimulation. The noise floor of the recording was roughly 15 uV and a large amount of multi-unit 
spikes cross the threshold for detecting spikes. The strongest and most reliable neuronal firing of 
layer IV in barrel cortex mostly occur during the air puff stimulation only but not the 
spontaneous recording after the third green vertical line indicating the end of whisker 
stimulation. The drug release trigger evoked electrical artifact recorded by the same 
microelectrode. The consequence of drug release trigger was very transient due to the procedure 
to carefully and completely separate the stimulation and recording circuit by utilization of 
separate counter electrodes. The recording counter and reference were shorted together to skull 
screw above the surface of ipsilateral motor cortex while the counter for the drug release trigger 
was a skull screw above the contralateral visual cortex. The artifact caused preamplifier 
saturation was only observed during the period of the trigger itself. Indicating the trigger was 
safe for further neural recordings. The same quantity of neural recording was observed across all 
DNQX release trials. The drug release effect was clearly observed. The air puff stimulation was 
delivered one second after the initiation of DNQX release trigger. The spike number during the 
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air puff as well as during the air puff interval were all decreased as a consequence of the DNQX 
release because high concentration of DNQX effectively block the fast AMPA receptor mediated 
glutamate transmission. Towards the end of the time frame demonstrated in this subfigure, the 
spike generation was already start to recover, because during the spontaneous recording, layer IV 
of barrel cortex usually generate limited quantity of spikes but the network already demonstrated 
firing rate higher than some of the previous drug affected sensory evoked spikes in the same plot. 
The recovered neural network activity seven seconds after the drug release trigger indicate the 
drug effect was completely washed away by seven seconds, the air puff stimulations and the 
intervals during the air puff all correspond to high firing rate. The firing pattern of the recorded 
channel was further analyzed by calculating the PSTH of sensory evoked multi-unit spikes. 
4.4.2.2 Released DNQX suppresses sensory evoked PSTH 
The evoked firing rate increase can be separated into direct air puff induced increase and 
indirect interval increase. The three air puff stimulation will be denoted as AP1, AP2 and AP3, 
with the sensory evoked and interval period designated as s (sensory) and i (interval). The six 
different period to quantify the firing rate is emphasized by the red and blue semitransparent box 
in Fig. 4-6A. Time 0 represent the start of the first air puff stimulation, during electrically evoked 
control trials without release, the raster plot indicate transient increase in firing rate immediately 
after the start of the air puff, towards the dnd of the AP1s period, the recorded neurons displayed 
increased firing rate compare to the baseline spontaneous firing, but the spike generation was 
evoked at different time points and less reliably compare to the spikes evoked at the starting of 
AP1s stimulation. The AP1i period exhibit very similar firing pattern in correspondance with the 
later pattern of AP1s. During the AP2s stimulation the evoked whisker response still maintain 
very high temporal precision and very low spiking latency after the stimulus started over the 
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quantified trials. However from the AP3s, the air puff evoked sensory spikes display less 
precision and slightly longer latency than the previous two stimuli. The effect was partially 
induced by the adaptation of neural activity due to high frequency strong sensory input. During 
all the interval period the generated spike numbers were similarly elevated compare to the 
spontaneous firing rate towards the end of the burst air puff stimulation, representaed by raster 
plot from 0.75 seconds to 1 second in Fig. 4-6A. The average spike counter was utilized to 
calculate Peri-Stimulus Time Histogram (PSTH) of the air puff burst stimulation in Fig. 4-6B. 
The sensory stimuli AP1s, AP2s and AP3s each evoked strong and instantaneous firing rate 
increase after the begininig of the stimuli, due to adaptation the firing rate quickly decreased 
from AP1s to AP3s, the average firing rate during the interval periods AP1i, AP2i and AP3i 
clearly revealed the spike generation after the air puff stimulation was affected by an oscillatory 
source but display less strength and consistency compare to the direct sensory air puff stimuli. 
The first sensory burst after drug release trials was compared directly to the electrically evoked 
firing pattern in Fig. 4-6A and B. In Fig. 4-6A, the DNQX release significantly decreased the 
spike generation probability during all the interval periods, the firing rate of AP2s and AP3s was 
also seriously affected by the DNQX release process,  The firing pattern of AP2s after DNQX 
delviery resembles the AP3s firing during the control trials. The air puff evoked sensory spikes 
displayed less precision and more latency after the drug delivery. During AP3s the effect was 
more pronounced so the reliability of the sensory evoked spikes was partially impaired by the 
DNQX release effect. Less spikes were generated compare to the AP3s response of control trials. 
All the DNQX effect was clearly quantifiable in the PSTH of Fig. 4-6B. The most affected time 
period from the PSTH was the intervals. The spike numbers generated during the interval period 
was nearly abolished after the DNQX release and the oscillatory firng rate increase cannot be 
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observed during the DNQX release affected trials. The spike number of the AP3s period was also 
greatly decreased from the control trials. 
 
 
Figure 4-6 Spike time raster plot and PSTH of control and DNQX release trials.  (A) The spike time of 
multi-unit action potentials were plotted as vertical bars following the air puff stimulation. The trials were re-aligned 
to the beginning of the first air puff. The black color trials on the top were the first sensory burst stimulus after the 
electrical trigger without DNQX. The red color denoted trials were the first sensory burst response after the DNQX 
release trials. During the control experiments, the third air puff evoked less precise and less consistent multi-unit 
activity compared to the AP1s and AP2s response. However the same reduction in precision and consistency was 
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observed in both AP2s and AP3s response following the DNQX release. Indicating the released DNQX can weaken 
the network response. (B) The average PSTH of air puff evoked sensory response following control and DNQX 
affected trials. During the control trials, higher number of spikes than the spontaneous firing was observed during all 
the sensory and interval periods, however during the DNQX release trials the firing rate during interval period was 
almost abolished and resembles the low firing rate pattern during spontaneous trials. The example multi-unit PSTH 
was averaged over 29 trials. 
 
4.4.2.3 DNQX release change firing rate in barrel cortex 
To quantitatively assess the effectiveness of released DNQX on the barrel cortex neural 
activity, the multi-unit spike numbers was accumulated in all sensory and interval periods to 
summarize the overall effect of the DNQX release. The starting time of air puff stimuli was 
realigned around the time of triggered DNQX released, denoted by 0 and the black vertical line. 
The dashed purple line indicate the first air puff evoked sensory response following the DNQX 
release or the control trials illustrated in Fig. 4-7. Both control spike number and the DNQX 
spike number displayed a slight decreasing trend at the beginning of the trials representing the 
effect of sensory adaptation on the neural network. Immediately follow the drug release or 
control trigger the sensory evoked spike number was greatly reduced after the DNQX release but 
not the control without DNQX. The effect was washed out by the second sensory stimulus 
occurred at 7 seconds after the drug release trigger. Steady spike number trend was observed 
after the DNQX and the control trigger for 10 additional air puff burst stimuli. The difference 
between the sensory evoked responses following the DNQX and control trigger was very small 
across the trials. Due to the observation of the early sensory spike adaptation effect, the spike 
number during the last seven air puff burst stimuli was averaged to serve as the baseline spike 
number for normalization. 
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Figure 4-7 DNQX release reduce the spike number of sensory evoked activity.  The total spike number 
from the beginning of air puff stimuli to the 0.75 seconds period in Fig. 4-7A was accumulated to represent the total 
neural activity evoked by the sensory input. During the control trials, the total spike number exhibit a smooth 
decreasing trend stabilized even after the release trigger without DNQX. The initial decrease in firing rate was 
caused by adaptation to the strong whisker stimulation. During the drug release trials, the spike number during the 
first air puff burst stimulus was discernibly different from the other consecutive air puff stimuli as well as the control 
trigger affected sensory response. The time 0 indicate the beginning of the DNQX release trigger, the purple vertical 
line indicate the first air puff stimulus following the DNQX release or control trigger. The second air puff stimulus 
evoked neural response was not affected by the released DNQX at all, indicating the neural network activity 7 
seconds after the DNQX release was recovered to the baseline. Multi-unit recording on 20 channels (from 3 
animals) was summarized in the figure.  
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4.4.2.4 Distinctive DNQX effect pattern on different network activity 
In Fig. 4-6A and B the spike number generated during the different period of air puff 
burst stimuli was profoundly different in the control trials. The multi-unit spike count for sensory 
evoked spikes was remarkably higher than the interval spikes and displayed strong adaptation 
effect, so the spike count during AP3s was noticeably lower than AP1s. The effect of released 
DNQX was different on the various periods of air puff evoked spikes. During the stronger neural 
activity the DNQX exhibit less effectiveness as demonstrated by Fig. 4-8. The AP1s evoked 
spikes had the highest spike count during control trials and the DNQX affected trials generate 
negligible impact on the spike number in this period. In contrast, the AP1i spikes had very low 
spike number thus were noticeably reduced by the release of DNQX, the spike number generated 
during AP1i was nearly 25% of the number generated during the control trials. As the adaptation 
reduces the spike number during whisker stimulation, the spike number as well as the precision 
of the spikes noticeably reduced during AP2s and AP3s. Releasing of DNQX generated 
remarkably higher impact on the multi-unit spike numbers during these periods, 25% reduction 
and 45% reduction compare to the baseline, respectively. The spike numbers generated during 
the interval of air puff was denoted as non-Sensory spikes due to the lack of direct multi-whisker 
stimuli input. The lower spike numbers during the non-Sensory neural network activity was more 
severely impacted by the release of DNQX molecules. 
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Figure 4-8 Distinctively affected sensory evoked response during air puff burst.  The evoked neural 
response by the burst air puff stimuli exhibit remarkably different patterns. The sensory evoked firing rate increase 
display high amplitude, high precision, low latency and strong adaptation effect over the stimuli. The interval spike 
numbers exhibit the opposite characteristics with lower amplitude and lower reliability. Each of the neural response 
was normalized to the baseline firing rate during the same interval. During AP1s, the firing rate was highest, 
although the time of AP1s was the closest to the delivery of DNQX, the firing rate was not influenced by the 
released DNQX at all. With the adaptation gradually decrease the firing rate of sensory evoked spikes, the AP2s and 
AP3s response was affected more by the release of DNQX molecules. To a sharp contrast, the action potential elicit 
during the interval time of the air puff was profoundly less than the sensory evoked spikes and the DNQX effect on 
the interval spikes was remarkably higher than the effect on sensory spikes. Multi-unit recording on 20 channels 
(from 3 animals) was summarized in the figure. 
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4.4.3 Characterization of DNQX release system in vivo 
4.4.3.1 DNQX effectiveness over trials 
The DNQX release system generated noticeable difference in spike numbers over 
multiple trials. During each trial, the 8 to 12 recording microelectrodes displayed unanimous 
reduction in multi-unit spike number. The channels without stable sensory evoked baseline firing 
rate was removed from the analysis and the summary of DNQX release effect over trials is 
illustrated in Fig 4-9. Because the multi-unit spike number during AP1s, AP2s and AP3s period 
was less noticeably impacted by the release of DNQX, all the summary of DNQX impact was 
calculated from averaging the spike numbers generated during AP1i, AP2i and AP3i. This 
account for a more precise quantification of DNQX effect, because the sensory evoked spikes 
were possibly driven by over-saturated synaptic input onto the neural network in barrel cortex. 
Although the DNQX can partially antagonize the input synaptic transmission onto these neurons, 
the networks were still driven by almost saturated neural input. The phenomenon is represented 
by the sigmoidal activation function of the neurons. So the sensory evoked spikes cannot 
represent the effectiveness of the DNQX. In Fig 4-9, the first DNQX release exhibit the most 
substantial impact on the total spike number. 90% of the spike number was reduced during the 
first trial of DNQX release. During the later trials, each DNQX release induced noticeable spike 
number reduction compare to the baseline spike numbers denoted as the red horizontal dash line. 
The general trend of drug release effectiveness was continuously reduced over the period of the 
experiment. Thus linear regression was fitted to the spike number trend over trials to capture the 
decrease in DNQX effect. Over the trials sensory evoked spike numbers displayed fluctuation 
because of the random fluctuation of spike numbers in vivo. Despite the high consistency of the 
air puff induced spikes, the interval spike numbers quantified for the drug delivery effect 
 119 
demonstrated less precision and lower repeatability, yet they account for a longer duration of the 
total air puff burst stimuli, thus sufficient time period was recorded to estimate the spike number 
during this process.  
 
 
Figure 4-9 In vivo effect of DNQX release on barrel neural networks over trials. The average action 
potential suppression effect was summarized during multiple DNQX release trials during the in vivo experiment. 
The action potential suppression was derived from the normalized spike count during the air puff interval period. 
Normalization baseline was calculated as the stable neural response during sensory evoked spikes after the DNQX 
release effect completely diminished. The maximum DNQX effect was observed during the first release trial and a 
slight decrease trend of DNQX effect was observed over the 29 drug release trials. The trial number was determined 
by the minimum number of recordable trials for each animal, affected by the anesthesia state and animal survival 
during acute recording. A linear function was fitted to the DNQX effect over trials. Fit quality reached 0.217, 
indicating a relatively weak correlation between the trial number and the DNQX efficacy. Multi-unit recordings on 
20 channels (from 3 animals) was illustrated in the figure. 
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4.4.3.2 The spatial resolution of DNQX release 
The spatial extend of the DNQX effect was estimated by observing the drug effect on 
various recording channels. The effect of drug molecules were estimated by the normalized spike 
number reduction compare to the sensory evoked baseline firing rate. The center recording 
electrode demonstrated the strongest normalized spike number reduction. The drug release effect 
from 3 in vivo animal experiments were summarized together to generate an estimate for the 
drug effective range in Fig. 4-10. The furthest electrode to record the drug release efficacy was 
325 μm away from the center of drug delivery. Although the result was affected by the random 
spike number fluctuation during the in vivo experiment and the change of brain state, a second 
order polynomial function was fitted to the reduction trend of the drug action with a quality 
factor of 0.658 in Fig. 4-10. The high fit quality of the polynomial function demonstrate the trend 
of DNQX action decrease over the distance. The extrapolation result from the fitted polynomial 
function indicate the drug was effective for up to 400 μm distance from the center of release. The 
in vivo drug efficacy gradually decrease as the distance from the center of release increased. This 
reflect the semi-sphere drug diffusion profile from the releasing electrode observed in vitro. 
Despite the influence of restricted diffusion in the tissue, the large number of trials of recording 
on various channels could account for the randomly distributed diffusion restriction patterns in 
vivo. 
121
Figure 4-10 The spatial extent of DNQX effect.  The normalized spike number generation during the air 
puff interval period of the drug release was quantified to estimate the effective range of the released DNQX. The 
maximum DNQX effect was observed in the center of delivery and the suppression efficacy decreased as the 
distance of the microelectrode from the center increased. A symmetric second order polynomial function describes 
the reduction trend of DNQX effect over a distance of 400 μm. The fitness reached quality factor of 0.658, 
indicating good trend for predicting the effectiveness of DNQX release. The released DNQX effectiveness was 
reduced to half efficacy by the distance of 310 μm as extrapolated by the fitted function. Multi-unit recording of 20 
channels (from 3 animals) was summarized, 29 trials of each multi-unit was averaged in the experiment.  
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4.5 DISCUSSION 
4.5.1 Benefit of double-layer DNQX conducting polymer 
 
The single layer PPy/CNT/DNQX polymer only maintain very limited quantity of DNQX 
on the microelectrodes. Due to the high value in microelectrode array fabrication as well as the 
extreme importance to ensure the success of in vivo experiments, the microelectrodes with 
DNQX coating requires large quantity of drug loading capacity. Increasing the coating capacity 
of PPy/CNT/DNQX by double-layer approach can significantly broaden the range of application 
for the drug release technique, because the benefit of PEDOT/CNT polymer on promoting the 
second layer deposition of PPy film with drug molecule is not affected by the choice of 
molecules or the difficulty in electrochemical synthesis. The PEDOT/CNT polymer improve the 
deposition of PPy/CNT/DNQX film by decreasing the initial impedance and increasing the 
surface area of the substrate for deposition. The beneficial effect was characterized by the 
remarkably reduced impedance across a broad range of measured frequencies. The incorporation 
of CNT into the PEDOT/CNT polymer as well as the PPy/CNT/DNQX polymer not only 
enhance the overall conductivity and the mechanical stability of the polymer, but also serve as 
the reservoir to release drug. Because high concentration DNQX solution was initially utilized to 
wet the interior surface of CNT, the conducting polymer sealed CNT in the PPy/CNT/DNQX 
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embed large quantity of DNQX molecules that could be driven out during the drug release by the 
concentration gradient created in the polymer matrix. 
4.5.2 Effectiveness of DNQX release in barrel cortex 
4.5.2.1 Benefit of barrel cortex for evaluating the technique 
The transient increase in action potential firing rate in the barrel cortex is strong and 
reliable. The topographical representation of facial whiskers by the barrel neural networks also 
enable the optimization of sensory evoked neural response by evoking neural activity on various 
facial whiskers and observe the quantity of generated multi-unit spikes. The quantifiable and 
repeatable spike number generated in the barrel cortex have been utilized to evaluate various 
neuromodulation techniques in the brain such as iontophoresis [47]. The barrel cortex neural 
network activity not only displayed the high precision high amplitude firing pattern directly 
evoked by the air puff stimuli, but also demonstrated relatively weak but still repeatable action 
potential firing patterns during the intervals of the air puff. The oscillatory neural networks 
activity observed during the intervals could be a result of network oscillation generated by 
interaction between excitatory and inhibitory neural networks [232], another possible mechanism 
for such neural activity is the residual mechanical vibration of the whisker after the air puff. The 
reliable quantity of the muti-unit activity in the barrel cortex represent one benefit of the barrel 
cortex as model system, the other benefit is the various techniques to evoke complex neural 
network activity patterns. For the further evaluation of the DNQX release technique, sequential 
stimulation to the principle whisker and adjacent whisker could possibly be utilized to elicit 
various patterns of neural network activity[231]. Furthermore, the non-barrel septa region of the 
layer IV of SI cortex neural networks may respond to axonal input from the POm nuclei of 
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thalamus [233]. Due the lack of detailed neural transmission mechanisms in the septa region and 
the more effective suppression of DNQX on relatively weak neural response. The drug delivery 
technique could find use in understanding the synaptic transmission in the septa region, with 
almost identical experiment preparation compare to the barrel cortex recording in this study.  
4.5.2.2 DNQX release affect the neural network activity in barrel cortex 
The optimal neural response to measure the DNQX release effect was the weaker neural 
network response during the interval of air puffs. Because of the spike activation function of the 
neuronal membrane potential [184], the overall input signal to the neurons during the air puff 
stimulation saturated the input of the neurons. So the released DNQX drive the membrane 
potential from oversaturated non-linear response range to the adaptive firing rate range of the 
neuron. Thus the effectiveness of the DNQX molecule was partially undetectable. However, 
during the relatively weaker neural activation period of the air puff interval, the neuronal 
membrane potential was near the threshold for firing action potentials, thus the DNQX release 
could effectively reduce the input to the neurons and subsequently noticeably reduce the firing 
probability of the neurons during this period. The spike numbers generated during the intervals 
of air puffs effectively represent the weaker neural transmission process in during the mechanical 
stimulation of whisker, because despite the low firing rate in this period, the baseline multi-unit 
spike numbers were still significantly higher than spontaneous spike numbers observed in layer 
IV of barrel cortex. 
4.5.2.3 DNQX release system demonstrate high spatial and temporal resolution 
The effect of the released DNQX molecule on the excitatory neural transmission was 
observed beyond one second from the trigger of the drug release. To prevent the strong 
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adaptation effect with frequent whisker stimulation, the drug effectiveness cannot be determined 
at very high temporal precision. Because the six seconds interval between each air puff burst 
allow the repetitive generation of multi-unit spikes with very stable baseline and little adaptation 
effect. The second air puff burst evoked sensory response was conducted 7 seconds following the 
release of DNQX and the observed DNQX effect was already washed out during this period. 
This high temporal resolution of pharmacological intervention technique allows the transient 
modulation of behavior neural states and prevent the occurrence of side effects caused by the 
drug molecules. The detailed temporal extent of the drug release system requires further 
investigation to improve the understanding of the drug release and diffusion dynamics during the 
process. The spatial extent of the DNQX release effect was examined by fitting second order 
polynomial function to the effective index of the specific channels. In the center of the 
neuromodulation, nearly complete abolish of neural activity was observed during the interval 
period of air puff, while on the electrode sites 300 μm away, the effectiveness reduced to nearly 
40% of the maximum capability. The released drug molecule from a planar MEA electrode could 
form a semi-sphere diffusion concentration of neural molecules, but the in vivo restricted 
diffusion of substance may alter the detailed distribution of the drug molecules being released. 
At a certain distance away the drug molecule reduces below the effective concentration of the 
drug thus the neural suppression cannot be observed. The decay of drug concentration roughly 
follows a second order polynomial function, where in the center the drug demonstrate maximum 
effect and the effectiveness decay rapidly towards the edge of the diffusion range. The function 
was restricted by the symmetricity of the diffusion pattern and the maximum effectiveness in the 
center of the electrode. The fitted function demonstrated high fit quality factor of 0.658. 
Indicating the reduction trend for drug release effectiveness index could be described as a 
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symmetric second order polynomial function. The extrapolation of the fitted function indicate the 
drug effect will be zero around 435 μm from the center of release and the effectiveness of half 
the maximum drug action is observed near 310 μm. Thus the overall spatial resolution of the 
drug release modulation to neural network with the drug release parameters of this experiment is 
around 600-900 μm depending on the required drug modulation intensity for the purpose of the 
device. The effect is sufficient to affect roughly one excitatory barrel neural networks in the layer 
IV of S1 cortex. The drug delivery dosage and spatial resolution of drug modulation could be 
altered in future studies by varying the electrical drug release trigger amplitude or duration. 
4.5.3 Drug release for therapeutic and behavior research device 
In a recent study, Simon et al. utilized PEDOT/PSS polymers to successful delivery 
neural molecules such as glutamate (Glu), aspartate (Asp) and γ-amino butyric acid (GABA) to 
peripheral auditory environment. However the device requires complicated fabrication process 
and is not capable of simultaneous neural recording of the affected neural networks. The bulky 
size of the device also added great difficulties to integrate the device onto in vivo MEAs. The in 
vivo feasibility of simultaneous localized drug release and direct recording of modulated neural 
networks has not been demonstrated thus requires further investigation. 
The drug release technique evaluated in this work demonstrated combination of multiple benefit 
towards implementing pharmaceutical modulation capability onto in vivo MEAs. The simple 
technique of coating conducting polymer directly onto specific sites of MEAs allow the 
incorporation of neuromolecules without additional device complexity such as microfluidic 
channels and cannulas or fiber optics for optogenetics. With the mechanical stability of the 
conducting polymer, the device could be implanted into the target neural tissue for long period 
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without losing the functionality. Any suitable neural stimulation device could be utilized to 
trigger the release of drug molecule from the conducting polymer coated microelectrodes. 
Additionally, different sites on the MEAs could incorporate various species of neuromolecules 
without interfering with each other. The neural modulation effect of multiple neuromolecules can 
be subsequently triggered simultaneously or in specifically designed spatial temporal patterns. 
The capability of the device to precisely deliver neuromolecules on demand also maximize the 
conservation of drug during the whole duration of the device implantation. For devices such as 
close-loop neural stimulation system for treating epilepsies based on the detection of abnormal 
neural activity, the drug delivery system can be easily adapted to maximize the suppression on 
neural activity without introducing additional complexity, and the drug release triggered by the 
detection of abnormal neural activity could provide long term effectiveness to the neural network 
intervention treatment with very small quantity of drug molecules incorporated in the conducting 
polymer film. 
4.6 CONCLUSIONS 
An electrochemically controlled DNQX release system was developed and evaluated in 
the somatosensory barrel cortex of the rats. Mechanical stimulation to the rat facial whisker 
evoked repetitive firing of action potentials in the barrel cortex neural network and this firing 
pattern was suppressed by the release of DNQX from implanted MEAs, evaluated by 
simultaneous neural recording and drug delivery. The effect of released DNQX lasted between 
one second and six seconds. The spatial extent of the drug release was estimated by observing 
the decay of DNQX effectiveness on distance recording microelectrodes. The range of DNQX 
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action was between 600 μm and 900 μm depending on the designated strength of drug action. 
Taken together, the system demonstrated successful in vivo neural network modulation capability 
with high spatial and temporal precision, the precisely controllable delivery of neuromolecules is 
promising for possible close-loop treatment device for neural disorders or in vivo functional 
neural network study in neuroscience research. 
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